

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549
FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file numbers: 001-34465

SELECT MEDICAL HOLDINGS CORPORATION

(Exact name of Registrant as specified in its Charter)

Delaware

20-1764048

(State or Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification Number)

4714 Gettysburg Road, P.O. Box 2034
Mechanicsburg, PA 17055
(Address of Principal Executive Offices and Zip code)
(717) 972-1100
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	SEM	New York Stock Exchange (NYSE)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging Growth Company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 31, 2022, Select Medical Holdings Corporation had outstanding 126,983,615 shares of common stock.

Unless the context indicates otherwise, any reference in this report to "Holdings" refers to Select Medical Holdings Corporation and any reference to "Select" refers to Select Medical Corporation, the wholly owned operating subsidiary of Holdings, and any of Select's subsidiaries. Any reference to "Concentra" refers to Concentra Group Holdings Parent, LLC ("Concentra Group Holdings Parent") and its subsidiaries, including Concentra Inc. References to the "Company," "we," "us," and "our" refer collectively to Holdings, Select, and Concentra.

TABLE OF CONTENTS

<u>PART I</u>	<u>FINANCIAL INFORMATION</u>	<u>3</u>
<u>ITEM 1.</u>	<u>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</u>	
	<u>Condensed consolidated balance sheets</u>	<u>3</u>
	<u>Condensed consolidated statements of operations</u>	<u>4</u>
	<u>Condensed consolidated statements of comprehensive income</u>	<u>5</u>
	<u>Condensed consolidated statements of changes in equity and income</u>	<u>6</u>
	<u>Condensed consolidated statements of cash flows</u>	<u>8</u>
	<u>Notes to condensed consolidated financial statements</u>	<u>9</u>
<u>ITEM 2.</u>	<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	<u>23</u>
<u>ITEM 3.</u>	<u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	<u>48</u>
<u>ITEM 4.</u>	<u>CONTROLS AND PROCEDURES</u>	<u>48</u>
<u>PART II</u>	<u>OTHER INFORMATION</u>	<u>49</u>
<u>ITEM 1.</u>	<u>LEGAL PROCEEDINGS</u>	<u>49</u>
<u>ITEM 1A.</u>	<u>RISK FACTORS</u>	<u>49</u>
<u>ITEM 2.</u>	<u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	<u>49</u>
<u>ITEM 3.</u>	<u>DEFAULTS UPON SENIOR SECURITIES</u>	<u>49</u>
<u>ITEM 4.</u>	<u>MINE SAFETY DISCLOSURES</u>	<u>49</u>
<u>ITEM 5.</u>	<u>OTHER INFORMATION</u>	<u>49</u>
<u>ITEM 6.</u>	<u>EXHIBITS</u>	<u>50</u>
	<u>SIGNATURES</u>	

PART I: FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Select Medical Holdings Corporation
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)

ASSETS	December 31, 2021	September 30, 2022
Current Assets:		
Cash and cash equivalents	\$ 74,310	\$ 108,223
Accounts receivable	889,303	909,030
Prepaid income taxes	55,620	19,227
Other current assets	120,206	180,766
Total Current Assets	1,139,439	1,217,246
Operating lease right-of-use assets	1,078,754	1,129,872
Property and equipment, net	961,467	957,353
Goodwill	3,448,912	3,479,374
Identifiable intangible assets, net	374,879	358,411
Other assets	356,720	412,720
Total Assets	\$ 7,360,171	\$ 7,554,976
LIABILITIES AND EQUITY		
Current Liabilities:		
Overdrafts	\$ 42,353	\$ 33,262
Current operating lease liabilities	229,334	234,595
Current portion of long-term debt and notes payable	17,572	43,429
Accounts payable	233,844	207,413
Accrued payroll	247,292	252,041
Accrued vacation	144,048	147,763
Accrued interest	29,002	10,347
Accrued other	244,312	265,451
Government advances	83,790	942
Unearned government assistance	93	236
Income taxes payable	1,437	1,265
Total Current Liabilities	1,273,077	1,196,744
Non-current operating lease liabilities	916,540	967,758
Long-term debt, net of current portion	3,556,385	3,750,411
Non-current deferred tax liability	142,792	162,156
Other non-current liabilities	106,442	109,848
Total Liabilities	5,995,236	6,186,917
Commitments and contingencies (Note 14)		
Redeemable non-controlling interests	39,033	33,540
Stockholders' Equity:		
Common stock, \$0.001 par value, 700,000,000 shares authorized, 133,884,817 and 127,144,158 shares issued and outstanding at 2021 and 2022, respectively	134	127
Capital in excess of par	504,314	444,843
Retained earnings	593,251	570,069
Accumulated other comprehensive income	12,282	90,556
Total Stockholders' Equity	1,109,981	1,105,595
Non-controlling interests	215,921	228,924
Total Equity	1,325,902	1,334,519
Total Liabilities and Equity	\$ 7,360,171	\$ 7,554,976

The accompanying notes are an integral part of these condensed consolidated financial statements.

Select Medical Holdings Corporation
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2021	2022	2021	2022
Revenue	\$ 1,534,221	\$ 1,567,794	\$ 4,644,704	\$ 4,752,082
Costs and expenses:				
Cost of services, exclusive of depreciation and amortization	1,297,682	1,393,817	3,882,579	4,191,377
General and administrative	37,885	39,491	109,025	114,272
Depreciation and amortization	50,128	51,459	150,702	153,579
Total costs and expenses	1,385,695	1,484,767	4,142,306	4,459,228
Other operating income	1,729	8,440	133,837	23,565
Income from operations	150,255	91,467	636,235	316,419
Other income and expense:				
Equity in earnings of unconsolidated subsidiaries	11,452	8,084	33,180	19,648
Interest income	—	—	4,749	—
Interest expense	(33,825)	(45,204)	(102,115)	(121,770)
Income before income taxes	127,882	54,347	572,049	214,297
Income tax expense	27,665	16,221	138,410	53,983
Net income	100,217	38,126	433,639	160,314
Less: Net income attributable to non-controlling interests	23,289	10,960	81,271	28,824
Net income attributable to Select Medical Holdings Corporation	<u>\$ 76,928</u>	<u>\$ 27,166</u>	<u>\$ 352,368</u>	<u>\$ 131,490</u>
Earnings per common share (Note 13):				
Basic and diluted	\$ 0.57	\$ 0.21	\$ 2.61	\$ 1.01

The accompanying notes are an integral part of these condensed consolidated financial statements.

Select Medical Holdings Corporation
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(in thousands)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2021	2022	2021	2022
Net income	\$ 100,217	\$ 38,126	\$ 433,639	\$ 160,314
Other comprehensive income (loss), net of tax:				
Gain (loss) on interest rate cash flow hedge	(536)	31,079	6,212	82,726
Reclassification adjustment for losses (gains) included in net income	12	(4,485)	18	(4,452)
Net change, net of tax benefit (expense) of \$182, \$(8,865), \$(2,166), and \$(26,092)	(524)	26,594	6,230	78,274
Comprehensive income	99,693	64,720	439,869	238,588
Less: Comprehensive income attributable to non-controlling interests	23,289	10,960	81,271	28,824
Comprehensive income attributable to Select Medical Holdings Corporation	<u>\$ 76,404</u>	<u>\$ 53,760</u>	<u>\$ 358,598</u>	<u>\$ 209,764</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

Select Medical Holdings Corporation
Condensed Consolidated Statements of Changes in Equity and Income
(unaudited)
(in thousands)

For the Nine Months Ended September 30, 2022

	Total Stockholders' Equity							
	Common Stock Issued	Common Stock Par Value	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Non- controlling Interests	Total Equity
Balance at December 31, 2021	133,884	\$ 134	\$ 504,314	\$ 593,251	\$ 12,282	\$ 1,109,981	\$ 215,921	\$ 1,325,902
Net income attributable to Select Medical Holdings Corporation				49,117		49,117		49,117
Net income attributable to non-controlling interests						—	4,891	4,891
Cash dividends declared for common stockholders (\$0.125 per share)				(16,691)		(16,691)		(16,691)
Issuance of restricted stock	13	0	0			—		—
Vesting of restricted stock			8,288			8,288		8,288
Repurchase of common shares	(2,128)	(2)	(23,459)	(28,215)		(51,676)		(51,676)
Issuance of non-controlling interests			651			651	4,578	5,229
Non-controlling interests acquired in business combination, measurement period adjustment						—	12,463	12,463
Distributions to and purchases of non-controlling interests						—	(9,097)	(9,097)
Redemption value adjustment on non-controlling interests				(1,381)		(1,381)		(1,381)
Other comprehensive income					39,853	39,853		39,853
Other				(2)		(2)		(2)
Balance at March 31, 2022	131,769	\$ 132	\$ 489,794	\$ 596,079	\$ 52,135	\$ 1,138,140	\$ 228,756	\$ 1,366,896
Net income attributable to Select Medical Holdings Corporation				55,207		55,207		55,207
Net income attributable to non-controlling interests						—	9,155	9,155
Cash dividends declared for common stockholders (\$0.125 per share)				(16,108)		(16,108)		(16,108)
Issuance of restricted stock	211	0	0			—		—
Forfeitures of unvested restricted stock	(6)	0	0	3		3		3
Vesting of restricted stock			8,406			8,406		8,406
Repurchase of common shares	(5,483)	(6)	(56,965)	(69,976)		(126,947)		(126,947)
Issuance of non-controlling interests						—	1,725	1,725
Distributions to and purchases of non-controlling interests			534			534	(7,348)	(6,814)
Redemption value adjustment on non-controlling interests				355		355		355
Other comprehensive income					11,827	11,827		11,827
Other				(4)		(4)		(4)
Balance at June 30, 2022	126,491	\$ 126	\$ 441,769	\$ 565,556	\$ 63,962	\$ 1,071,413	\$ 232,288	\$ 1,303,701
Net income attributable to Select Medical Holdings Corporation				27,166		27,166		27,166
Net income attributable to non-controlling interests						—	8,720	8,720
Cash dividends declared for common stockholders (\$0.125 per share)				(15,893)		(15,893)		(15,893)
Issuance of restricted stock	1,228	1	(1)			—		—
Forfeitures of unvested restricted stock	(6)	0	0	3		3		3
Vesting of restricted stock			9,649			9,649		9,649
Repurchase of common shares	(569)	0	(6,574)	(8,417)		(14,991)		(14,991)
Issuance of non-controlling interests						—	142	142
Distributions to and purchases of non-controlling interests				(2,450)		(2,450)	(12,226)	(14,676)
Redemption value adjustment on non-controlling interests				4,108		4,108		4,108
Other comprehensive income					26,594	26,594		26,594
Other				(4)		(4)		(4)
Balance at September 30, 2022	127,144	\$ 127	\$ 444,843	\$ 570,069	\$ 90,556	\$ 1,105,595	\$ 228,924	\$ 1,334,519

The accompanying notes are an integral part of these condensed consolidated financial statements.

For the Nine Months Ended September 30, 2021

	Total Stockholders' Equity							
	Common Stock Issued	Common Stock Par Value	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity	Non-controlling Interests	Total Equity
Balance at December 31, 2020	134,850	\$ 135	\$ 509,128	\$ 553,244	\$ (2,027)	\$ 1,060,480	\$ 192,493	\$ 1,252,973
Net income attributable to Select Medical Holdings Corporation				110,546		110,546		110,546
Net income attributable to non-controlling interests						—	17,042	17,042
Issuance of restricted stock	2	0	0			—		—
Forfeitures of unvested restricted stock	(14)	0	0			—		—
Vesting of restricted stock			6,173			6,173		6,173
Non-controlling interests acquired in business combination						—	8,193	8,193
Distributions to and purchases of non-controlling interests			(787)			(787)	(13,458)	(14,245)
Redemption value adjustment on non-controlling interests				(38,405)		(38,405)		(38,405)
Other comprehensive income					8,151	8,151		8,151
Other			(178)	(4)		(182)	371	189
Balance at March 31, 2021	134,838	\$ 135	\$ 514,336	\$ 625,381	\$ 6,124	\$ 1,145,976	\$ 204,641	\$ 1,350,617
Net income attributable to Select Medical Holdings Corporation				164,894		164,894		164,894
Net income attributable to non-controlling interests						—	13,241	13,241
Cash dividends declared for common stockholders (\$0.125 per share)				(16,876)		(16,876)		(16,876)
Issuance of restricted stock	211	0	0			—		—
Forfeitures of unvested restricted stock	(2)	0	0			—		—
Vesting of restricted stock			6,564			6,564		6,564
Repurchase of common shares	(42)	0	(707)	(903)		(1,610)		(1,610)
Issuance of non-controlling interests			(1,051)			(1,051)	6,739	5,688
Distributions to and purchases of non-controlling interests			(2,970)			(2,970)	(9,324)	(12,294)
Redemption value adjustment on non-controlling interests				(59,370)		(59,370)		(59,370)
Other comprehensive loss					(1,397)	(1,397)		(1,397)
Other				65		65	370	435
Balance at June 30, 2021	135,005	\$ 135	\$ 516,172	\$ 713,191	\$ 4,727	\$ 1,234,225	\$ 215,667	\$ 1,449,892
Net income attributable to Select Medical Holdings Corporation				76,928		76,928		76,928
Net income attributable to non-controlling interests						—	10,709	10,709
Cash dividends declared for common stockholders (\$0.125 per share)				(16,940)		(16,940)		(16,940)
Issuance of restricted stock	954	1	(1)			—		—
Forfeitures of unvested restricted stock	(2)	0	0			—		—
Vesting of restricted stock			7,659			7,659		7,659
Repurchase of common shares	(1,813)	(2)	(26,712)	(37,726)		(64,440)		(64,440)
Issuance of non-controlling interests			4,592			4,592	9,646	14,238
Distributions to and purchases of non-controlling interests						—	(18,278)	(18,278)
Redemption value adjustment on non-controlling interests				(96,000)		(96,000)		(96,000)
Other comprehensive loss					(524)	(524)		(524)
Other				(2)		(2)	370	368
Balance at September 30, 2021	134,144	\$ 134	\$ 501,710	\$ 639,451	\$ 4,203	\$ 1,145,498	\$ 218,114	\$ 1,363,612

The accompanying notes are an integral part of these condensed consolidated financial statements.

Select Medical Holdings Corporation
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)

	For the Nine Months Ended September 30,	
	2021	2022
Operating activities		
Net income	\$ 433,639	\$ 160,314
Adjustments to reconcile net income to net cash provided by operating activities:		
Distributions from unconsolidated subsidiaries	27,772	16,892
Depreciation and amortization	150,702	153,579
Provision for expected credit losses	172	(41)
Equity in earnings of unconsolidated subsidiaries	(33,180)	(19,648)
Gain on sale or disposal of assets	(87)	(1,593)
Stock compensation expense	22,002	27,956
Amortization of debt discount, premium and issuance costs	1,655	1,696
Deferred income taxes	(11,965)	(7,080)
Changes in operating assets and liabilities, net of effects of business combinations:		
Accounts receivable	645	(19,686)
Other current assets	(1,822)	2,923
Other assets	(3,124)	9,650
Accounts payable	22,914	(22,185)
Accrued expenses	84,796	15,989
Government advances	(165,470)	(82,848)
Unearned government assistance	(80,193)	143
Income taxes	13,524	36,220
Net cash provided by operating activities	<u>461,980</u>	<u>272,281</u>
Investing activities		
Business combinations, net of cash acquired	(26,830)	(22,027)
Purchases of property and equipment	(125,386)	(135,119)
Investment in businesses	(16,367)	(17,323)
Proceeds from sale of assets	11,257	5,364
Net cash used in investing activities	<u>(157,326)</u>	<u>(169,105)</u>
Financing activities		
Borrowings on revolving facilities	—	845,000
Payments on revolving facilities	—	(625,000)
Borrowings of other debt	19,515	20,866
Principal payments on other debt	(22,910)	(25,165)
Dividends paid to common stockholders	(33,816)	(48,692)
Repurchase of common stock	(66,050)	(193,614)
Decrease in overdrafts	—	(9,091)
Proceeds from issuance of non-controlling interests	19,926	7,096
Distributions to and purchases of non-controlling interests	(50,397)	(40,663)
Net cash used in financing activities	<u>(133,732)</u>	<u>(69,263)</u>
Net increase in cash and cash equivalents	170,922	33,913
Cash and cash equivalents at beginning of period	577,061	74,310
Cash and cash equivalents at end of period	<u>\$ 747,983</u>	<u>\$ 108,223</u>
Supplemental information		
Cash paid for interest, excluding amounts received of \$6,232 under interest rate cash flow hedge for the nine months ended September 30, 2022	\$ 118,570	\$ 143,455
Cash paid for taxes	136,857	24,844

The accompanying notes are an integral part of these condensed consolidated financial statements.

SELECT MEDICAL HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings, Select, and Select’s subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of September 30, 2022, and for the three and nine month periods ended September 30, 2021 and 2022, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.

2. Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

3. Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.

Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk. Approximately 15% and 17% of the Company’s accounts receivable is due from Medicare at December 31, 2021 and September 30, 2022, respectively.

4. Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their approximate redemption values, after the attribution of net income or loss.

The changes in redeemable non-controlling interests are as follows:

	Nine Months Ended September 30,	
	2021	2022
	(in thousands)	
Balance as of January 1	\$ 398,171	\$ 39,033
Net income attributable to redeemable non-controlling interests	9,626	1,918
Distributions to and purchases of redeemable non-controlling interests	(614)	(1,198)
Redemption value adjustment on redeemable non-controlling interests	38,405	1,381
Other	343	536
Balance as of March 31	\$ 445,931	\$ 41,670
Net income attributable to redeemable non-controlling interests	18,073	1,900
Distributions to and purchases of redeemable non-controlling interests	(1,987)	(1,553)
Redemption value adjustment on redeemable non-controlling interests	59,370	(355)
Other	165	535
Balance as of June 30	\$ 521,552	\$ 42,197
Net income attributable to redeemable non-controlling interests	12,580	2,240
Distributions to and purchases of redeemable non-controlling interests	(2,967)	(7,325)
Redemption value adjustment on redeemable non-controlling interests	96,000	(4,108)
Other	165	536
Balance as of September 30	\$ 627,330	\$ 33,540

5. Variable Interest Entities

Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians and from exercising control over medical decisions by physicians. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians, which, in turn, employ or contract with physicians who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices to new licensed physicians at any time. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

As of December 31, 2021, and September 30, 2022, the total assets of the Company’s variable interest entities were \$225.1 million and \$264.0 million, respectively, and are principally comprised of accounts receivable. As of December 31, 2021, and September 30, 2022, the total liabilities of the Company’s variable interest entities were \$74.8 million and \$87.3 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of \$150.3 million and \$179.8 million as of December 31, 2021, and September 30, 2022, respectively. These intercompany balances are eliminated in consolidation.

6. Leases

The Company has operating and finance leases for its facilities. The Company leases its corporate office space from related parties.

The Company's total lease cost is as follows:

	Three Months Ended September 30, 2021			Three Months Ended September 30, 2022		
	Unrelated Parties	Related Parties	Total	Unrelated Parties	Related Parties	Total
	(in thousands)					
Operating lease cost	\$ 71,647	\$ 1,791	\$ 73,438	\$ 73,795	\$ 1,810	\$ 75,605
Finance lease cost:						
Amortization of right-of-use assets	156	—	156	381	—	381
Interest on lease liabilities	270	—	270	335	—	335
Short-term lease cost	—	—	—	24	—	24
Variable lease cost	13,147	141	13,288	14,855	141	14,996
Sublease income	(2,253)	—	(2,253)	(1,963)	—	(1,963)
Total lease cost	<u>\$ 82,967</u>	<u>\$ 1,932</u>	<u>\$ 84,899</u>	<u>\$ 87,427</u>	<u>\$ 1,951</u>	<u>\$ 89,378</u>
	(in thousands)					
	Nine Months Ended September 30, 2021			Nine Months Ended September 30, 2022		
	Unrelated Parties	Related Parties	Total	Unrelated Parties	Related Parties	Total
	(in thousands)					
Operating lease cost	\$ 212,500	\$ 5,388	\$ 217,888	\$ 221,726	\$ 5,428	\$ 227,154
Finance lease cost:						
Amortization of right-of-use assets	296	—	296	1,105	—	1,105
Interest on lease liabilities	775	—	775	1,011	—	1,011
Short-term lease cost	—	—	—	74	—	74
Variable lease cost	39,242	285	39,527	42,917	321	43,238
Sublease income	(6,716)	—	(6,716)	(5,869)	—	(5,869)
Total lease cost	<u>\$ 246,097</u>	<u>\$ 5,673</u>	<u>\$ 251,770</u>	<u>\$ 260,964</u>	<u>\$ 5,749</u>	<u>\$ 266,713</u>

Supplemental cash flow information related to leases is as follows:

	Nine Months Ended September 30,	
	2021	2022
	(in thousands)	
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 219,754	\$ 232,472
Operating cash flows for finance leases	775	1,011
Financing cash flows for finance leases	273	1,086
Right-of-use assets obtained in exchange for lease liabilities:		
Operating leases	\$ 215,568	\$ 240,185
Finance leases	436	495

Supplemental balance sheet information related to leases is as follows:

	December 31, 2021			September 30, 2022		
	Unrelated Parties	Related Parties	Total	Unrelated Parties	Related Parties	Total
(in thousands)						
Operating Leases						
Operating lease right-of-use assets	\$ 1,052,603	\$ 26,151	\$ 1,078,754	\$ 1,108,127	\$ 21,745	\$ 1,129,872
Current operating lease liabilities	\$ 222,865	\$ 6,469	\$ 229,334	\$ 230,433	\$ 4,162	\$ 234,595
Non-current operating lease liabilities	894,104	22,436	916,540	947,828	19,930	967,758
Total operating lease liabilities	\$ 1,116,969	\$ 28,905	\$ 1,145,874	\$ 1,178,261	\$ 24,092	\$ 1,202,353
(in thousands)						
Finance Leases						
Property and equipment, net	\$ 8,505	\$ —	\$ 8,505	\$ 7,947	\$ —	\$ 7,947
Current portion of long-term debt and notes payable	\$ 1,404	\$ —	\$ 1,404	\$ 1,593	\$ —	\$ 1,593
Long-term debt, net of current portion	16,679	—	16,679	15,898	—	15,898
Total finance lease liabilities	\$ 18,083	\$ —	\$ 18,083	\$ 17,491	\$ —	\$ 17,491

The weighted average remaining lease terms and discount rates are as follows:

	December 31, 2021	September 30, 2022
Weighted average remaining lease term (in years):		
Operating leases	7.8	7.7
Finance leases	24.7	24.6
Weighted average discount rate:		
Operating leases	5.6 %	5.7 %
Finance leases	7.4 %	7.4 %

As of September 30, 2022, maturities of lease liabilities are approximately as follows:

	Operating Leases	Finance Leases
	(in thousands)	
2022 (remainder of year)	\$ 76,457	\$ 708
2023	284,911	2,868
2024	246,800	2,505
2025	203,253	2,227
2026	170,756	2,157
Thereafter	583,337	28,300
Total undiscounted cash flows	1,565,514	38,765
Less: Imputed interest	363,161	21,274
Total discounted lease liabilities	\$ 1,202,353	\$ 17,491

7. Intangible Assets

Goodwill

The following table shows changes in the carrying amounts of goodwill by reporting unit for the nine months ended September 30, 2022:

	<u>Critical Illness Recovery Hospital</u>	<u>Rehabilitation Hospital</u>	<u>Outpatient Rehabilitation</u>	<u>Concentra</u>	<u>Total</u>
	(in thousands)				
Balance as of December 31, 2021	\$ 1,131,440	\$ 442,155	\$ 654,125	\$ 1,221,192	\$ 3,448,912
Acquisition of businesses	6,505	—	6,779	3,927	17,211
Measurement period adjustment	13,251	—	—	—	13,251
Balance as of September 30, 2022	<u>\$ 1,151,196</u>	<u>\$ 442,155</u>	<u>\$ 660,904</u>	<u>\$ 1,225,119</u>	<u>\$ 3,479,374</u>

Identifiable Intangible Assets

The following table provides the gross carrying amounts, accumulated amortization, and net carrying amounts for the Company's identifiable intangible assets:

	<u>December 31, 2021</u>			<u>September 30, 2022</u>		
	<u>Gross Carrying Amount</u>	<u>Accumulated Amortization</u>	<u>Net Carrying Amount</u>	<u>Gross Carrying Amount</u>	<u>Accumulated Amortization</u>	<u>Net Carrying Amount</u>
	(in thousands)					
Indefinite-lived intangible assets:						
Trademarks	\$ 166,698	\$ —	\$ 166,698	\$ 166,698	\$ —	\$ 166,698
Certificates of need	21,478	—	21,478	22,999	—	22,999
Accreditations	1,874	—	1,874	1,874	—	1,874
Finite-lived intangible assets:						
Trademarks	5,000	(5,000)	—	5,000	(5,000)	—
Customer relationships	304,289	(141,111)	163,178	309,109	(162,875)	146,234
Non-compete agreements	36,746	(15,095)	21,651	38,434	(17,828)	20,606
Total identifiable intangible assets	<u>\$ 536,085</u>	<u>\$ (161,206)</u>	<u>\$ 374,879</u>	<u>\$ 544,114</u>	<u>\$ (185,703)</u>	<u>\$ 358,411</u>

The Company's accreditations and trademarks have renewal terms, and the costs to renew these intangible assets are expensed as incurred. At September 30, 2022, the accreditations and trademarks have a weighted average time until next renewal of 1.5 years and 7.0 years, respectively.

The Company's finite-lived intangible assets amortize over their estimated useful lives. Amortization expense was \$7.4 million and \$7.7 million for the three months ended September 30, 2021 and 2022, respectively. Amortization expense was \$21.8 million and \$23.0 million for the nine months ended September 30, 2021 and 2022, respectively.

8. Long-Term Debt and Notes Payable

As of September 30, 2022, the Company's long-term debt and notes payable are as follows:

	Principal Outstanding	Unamortized Premium (Discount)	Unamortized Issuance Costs	Carrying Value	Fair Value
	(in thousands)				
6.250% senior notes	\$ 1,225,000	\$ 23,082	\$ (11,706)	\$ 1,236,376	\$ 1,150,300
Credit facilities:					
Revolving facility	380,000	—	—	380,000	378,575
Term loan	2,103,437	(4,883)	(5,323)	2,093,231	2,035,075
Other debt, including finance leases	84,387	—	(154)	84,233	84,233
Total debt	<u>\$ 3,792,824</u>	<u>\$ 18,199</u>	<u>\$ (17,183)</u>	<u>\$ 3,793,840</u>	<u>\$ 3,648,183</u>

Principal maturities of the Company's long-term debt and notes payable are approximately as follows:

	2022	2023	2024	2025	2026	Thereafter	Total
	(in thousands)						
6.250% senior notes	\$ —	\$ —	\$ —	\$ —	\$ 1,225,000	\$ —	\$ 1,225,000
Credit facilities:							
Revolving facility	—	—	380,000	—	—	—	380,000
Term loan	—	4,757	11,150	2,087,530	—	—	2,103,437
Other debt, including finance leases	6,890	36,409	26,177	1,940	1,307	11,664	84,387
Total debt	<u>\$ 6,890</u>	<u>\$ 41,166</u>	<u>\$ 417,327</u>	<u>\$ 2,089,470</u>	<u>\$ 1,226,307</u>	<u>\$ 11,664</u>	<u>\$ 3,792,824</u>

As of December 31, 2021, the Company's long-term debt and notes payable are as follows:

	Principal Outstanding	Unamortized Premium (Discount)	Unamortized Issuance Costs	Carrying Value	Fair Value
	(in thousands)				
6.250% senior notes	\$ 1,225,000	\$ 27,635	\$ (13,951)	\$ 1,238,684	\$ 1,297,104
Credit facilities:					
Revolving facility	160,000	—	—	160,000	159,400
Term loan	2,103,437	(6,386)	(6,961)	2,090,090	2,087,661
Other debt, including finance leases	85,398	—	(215)	85,183	85,183
Total debt	<u>\$ 3,573,835</u>	<u>\$ 21,249</u>	<u>\$ (21,127)</u>	<u>\$ 3,573,957</u>	<u>\$ 3,629,348</u>

9. Interest Rate Cap

The Company is subject to market risk exposure arising from changes in interest rates on its term loan, which bears interest at a rate that is indexed to one-month LIBOR. The Company's objective in using an interest rate derivative is to mitigate its exposure to increases in interest rates. The interest rate cap limits the Company's exposure to increases in the one-month LIBOR rate to 1.0% on \$2.0 billion of principal outstanding under the term loan, as the interest rate cap provides for payments from the counterparty when interest rates rise above 1.0%. The interest rate cap has a \$2.0 billion notional amount and is effective through September 30, 2024. The Company will pay a monthly premium for the interest rate cap over the term of the agreement. The annual premium is equal to 0.0916% of the notional amount, or approximately \$1.8 million.

The interest rate cap has been designated as a cash flow hedge and is highly effective at offsetting the changes in cash outflows when one-month LIBOR exceeds 1.0%. Changes in the fair value of the interest rate cap, net of tax, are recognized in other comprehensive income and are reclassified out of accumulated other comprehensive income and into interest expense when the hedged interest obligations affect earnings.

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Nine Months Ended September 30,	
	2021	2022
	(in thousands)	
Balance as of January 1	\$ (2,027)	\$ 12,282
Gain on interest rate cap cash flow hedge	8,151	39,814
Amounts reclassified from accumulated other comprehensive income	—	39
Balance as of March 31	\$ 6,124	\$ 52,135
Gain (loss) on interest rate cap cash flow hedge	(1,403)	11,833
Amounts reclassified from accumulated other comprehensive income	6	(6)
Balance as of June 30	\$ 4,727	\$ 63,962
Gain (loss) on interest rate cap cash flow hedge	(536)	31,079
Amounts reclassified from accumulated other comprehensive income	12	(4,485)
Balance as of September 30	<u>\$ 4,203</u>	<u>\$ 90,556</u>

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

Statement of Operations	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
	(in thousands)			
Gains (losses) included in interest expense	\$ (16)	\$ 5,980	\$ (23)	\$ 5,936
Income tax benefit (expense)	4	(1,495)	5	(1,484)
Amounts reclassified from accumulated other comprehensive income	<u>\$ (12)</u>	<u>\$ 4,485</u>	<u>\$ (18)</u>	<u>\$ 4,452</u>

The Company expects that approximately \$63.5 million of estimated pre-tax gains will be reclassified from accumulated other comprehensive income into interest expense within the next twelve months.

Refer to Note 10 – Fair Value of Financial Instruments for information on the fair value of the Company’s interest rate cap contract and its balance sheet classification.

10. Fair Value of Financial Instruments

Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:

- Level 1 – inputs are based upon quoted prices for identical instruments in active markets.
- Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.
- Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.

The Company’s interest rate cap contract is recorded at its fair value in the condensed consolidated balance sheets on a recurring basis. The fair value of the interest rate cap contract is based upon a model-derived valuation using observable market inputs, such as interest rates and interest rate volatility, and the strike price.

Financial Instrument	Balance Sheet Classification	Level	December 31, 2021	September 30, 2022
(in thousands)				
Asset:				
Interest rate cap contract, current portion	Other current assets	Level 2	\$ —	\$ 63,192
Interest rate cap contract, non-current portion	Other assets	Level 2	18,055	59,993
Liability:				
Interest rate cap contract, current portion	Accrued other	Level 2	\$ 330	\$ —

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the credit facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the senior notes is based on quoted market prices. The carrying value of the Company's other debt, as disclosed in Note 8 – Long-Term Debt and Notes Payable, approximates fair value.

Financial Instrument	Level	December 31, 2021		September 30, 2022	
		Carrying Value	Fair Value	Carrying Value	Fair Value
(in thousands)					
6.250% senior notes	Level 2	\$ 1,238,684	\$ 1,297,104	\$ 1,236,376	\$ 1,150,300
Credit facilities:					
Revolving facility	Level 2	160,000	159,400	380,000	378,575
Term loan	Level 2	2,090,090	2,087,661	2,093,231	2,035,075

The Company's other financial instruments, which primarily consist of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.

11. Segment Information

The Company's reportable segments consist of the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. Other activities include the Company's corporate shared services, certain investments, and employee leasing services with non-consolidating subsidiaries.

The Company evaluates the performance of its segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company's reportable segments.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
(in thousands)				
Revenue:				
Critical illness recovery hospital	\$ 530,646	\$ 524,584	\$ 1,669,577	\$ 1,672,247
Rehabilitation hospital	212,434	229,387	632,904	678,908
Outpatient rehabilitation	274,540	284,993	806,910	844,191
Concentra	442,190	444,576	1,321,402	1,309,356
Other	74,411	84,254	213,911	247,380
Total Company	\$ 1,534,221	\$ 1,567,794	\$ 4,644,704	\$ 4,752,082
Adjusted EBITDA:				
Critical illness recovery hospital	\$ 57,245	\$ 11,013	\$ 243,421	\$ 66,999
Rehabilitation hospital	44,076	49,772	145,378	141,996
Outpatient rehabilitation	38,762	25,715	110,724	85,912
Concentra ⁽¹⁾	99,832	90,025	318,907	272,101
Other ⁽¹⁾	(31,338)	(23,412)	(9,491)	(69,054)
Total Company	\$ 208,577	\$ 153,113	\$ 808,939	\$ 497,954
Total assets:				
Critical illness recovery hospital	\$ 2,181,405	\$ 2,368,968	\$ 2,181,405	\$ 2,368,968
Rehabilitation hospital	1,191,093	1,189,486	1,191,093	1,189,486
Outpatient rehabilitation	1,339,452	1,377,010	1,339,452	1,377,010
Concentra	2,609,361	2,309,392	2,609,361	2,309,392
Other	578,162	310,120	578,162	310,120
Total Company	\$ 7,899,473	\$ 7,554,976	\$ 7,899,473	\$ 7,554,976
Purchases of property and equipment:				
Critical illness recovery hospital	\$ 12,365	\$ 21,534	\$ 43,249	\$ 60,631
Rehabilitation hospital	4,366	392	8,288	11,487
Outpatient rehabilitation	9,481	10,098	24,264	28,826
Concentra	11,353	9,074	31,624	28,030
Other	11,379	844	17,961	6,145
Total Company	\$ 48,944	\$ 41,942	\$ 125,386	\$ 135,119

(1) For the three and nine months ended September 30, 2022 and 2021, Adjusted EBITDA includes other operating income related to the recognition of payments received under the Provider Relief Fund for health care related expenses and loss of revenue attributable to the coronavirus disease 2019 ("COVID-19").

Adjusted EBITDA for the Concentra segment includes \$1.6 million and \$33.8 million of this income for the three and nine months ended September 30, 2021, respectively.

Adjusted EBITDA for the Company's other activities includes \$0.1 million and \$8.1 million of this income for the three months ended September 30, 2021 and 2022, respectively, and \$82.0 million and \$23.2 million for the nine months ended September 30, 2021 and 2022, respectively.

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

Three Months Ended September 30, 2021						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
	(in thousands)					
Adjusted EBITDA	\$ 57,245	\$ 44,076	\$ 38,762	\$ 99,832	\$ (31,338)	
Depreciation and amortization	(12,972)	(6,869)	(7,319)	(20,419)	(2,549)	
Stock compensation expense	—	—	—	(535)	(7,659)	
Income (loss) from operations	\$ 44,273	\$ 37,207	\$ 31,443	\$ 78,878	\$ (41,546)	\$ 150,255
Equity in earnings of unconsolidated subsidiaries						11,452
Interest expense						(33,825)
Income before income taxes						<u>\$ 127,882</u>

Three Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
	(in thousands)					
Adjusted EBITDA	\$ 11,013	\$ 49,772	\$ 25,715	\$ 90,025	\$ (23,412)	
Depreciation and amortization	(16,055)	(6,994)	(8,157)	(17,781)	(2,472)	
Stock compensation expense	—	—	—	(535)	(9,652)	
Income (loss) from operations	\$ (5,042)	\$ 42,778	\$ 17,558	\$ 71,709	\$ (35,536)	\$ 91,467
Equity in earnings of unconsolidated subsidiaries						8,084
Interest expense						(45,204)
Income before income taxes						<u>\$ 54,347</u>

Nine Months Ended September 30, 2021						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
	(in thousands)					
Adjusted EBITDA	\$ 243,421	\$ 145,378	\$ 110,724	\$ 318,907	\$ (9,491)	
Depreciation and amortization	(38,958)	(20,868)	(21,855)	(61,547)	(7,474)	
Stock compensation expense	—	—	—	(1,606)	(20,396)	
Income (loss) from operations	\$ 204,463	\$ 124,510	\$ 88,869	\$ 255,754	\$ (37,361)	\$ 636,235
Equity in earnings of unconsolidated subsidiaries						33,180
Interest income						4,749
Interest expense						(102,115)
Income before income taxes						<u>\$ 572,049</u>

Nine Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
	(in thousands)					
Adjusted EBITDA	\$ 66,999	\$ 141,996	\$ 85,912	\$ 272,101	\$ (69,054)	
Depreciation and amortization	(45,276)	(20,971)	(24,316)	(55,323)	(7,693)	
Stock compensation expense	—	—	—	(1,606)	(26,350)	
Income (loss) from operations	\$ 21,723	\$ 121,025	\$ 61,596	\$ 215,172	\$ (103,097)	\$ 316,419
Equity in earnings of unconsolidated subsidiaries						19,648
Interest expense						(121,770)
Income before income taxes						<u>\$ 214,297</u>

12. Revenue from Contracts with Customers

The following tables disaggregate the Company's revenue for the three and nine months ended September 30, 2021 and 2022:

Three Months Ended September 30, 2021						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Patient service revenue:						
Medicare	\$ 201,337	\$ 105,512	\$ 45,779	\$ 322	\$ —	\$ 352,950
Non-Medicare	324,857	96,326	210,877	440,145	—	1,072,205
Total patient services revenues	526,194	201,838	256,656	440,467	—	1,425,155
Other revenue	4,452	10,596	17,884	1,723	74,411	109,066
Total revenue	<u>\$ 530,646</u>	<u>\$ 212,434</u>	<u>\$ 274,540</u>	<u>\$ 442,190</u>	<u>\$ 74,411</u>	<u>\$ 1,534,221</u>
Three Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Patient service revenue:						
Medicare	\$ 201,558	\$ 106,584	\$ 45,193	\$ 205	\$ —	\$ 353,540
Non-Medicare	320,896	111,509	221,275	443,040	—	1,096,720
Total patient services revenues	522,454	218,093	266,468	443,245	—	1,450,260
Other revenue	2,130	11,294	18,525	1,331	84,254	117,534
Total revenue	<u>\$ 524,584</u>	<u>\$ 229,387</u>	<u>\$ 284,993</u>	<u>\$ 444,576</u>	<u>\$ 84,254</u>	<u>\$ 1,567,794</u>
Nine Months Ended September 30, 2021						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Patient service revenue:						
Medicare	\$ 634,675	\$ 311,752	\$ 127,361	\$ 847	\$ —	\$ 1,074,635
Non-Medicare	1,026,938	290,111	629,589	1,314,924	—	3,261,562
Total patient services revenues	1,661,613	601,863	756,950	1,315,771	—	4,336,197
Other revenue	7,964	31,041	49,960	5,631	213,911	308,507
Total revenue	<u>\$ 1,669,577</u>	<u>\$ 632,904</u>	<u>\$ 806,910</u>	<u>\$ 1,321,402</u>	<u>\$ 213,911</u>	<u>\$ 4,644,704</u>
Nine Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Patient service revenue:						
Medicare	\$ 634,225	\$ 314,635	\$ 131,530	\$ 577	\$ —	\$ 1,080,967
Non-Medicare	1,031,000	331,652	660,345	1,304,865	—	3,327,862
Total patient services revenues	1,665,225	646,287	791,875	1,305,442	—	4,408,829
Other revenue	7,022	32,621	52,316	3,914	247,380	343,253
Total revenue	<u>\$ 1,672,247</u>	<u>\$ 678,908</u>	<u>\$ 844,191</u>	<u>\$ 1,309,356</u>	<u>\$ 247,380</u>	<u>\$ 4,752,082</u>

13. Earnings per Share

The Company’s capital structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), the Company applies the two-class method because the Company’s unvested restricted stock awards are participating securities which are entitled to participate equally with the Company’s common stock in undistributed earnings. Application of the Company’s two-class method is as follows:

- (i) Net income attributable to the Company is reduced by the amount of dividends declared and by the contractual amount of dividends that must be paid for the current period for each class of stock. There were no contractual dividends paid for the three and nine months ended September 30, 2021 and 2022.
- (ii) The remaining undistributed net income of the Company is then equally allocated to its common stock and unvested restricted stock awards, as if all of the earnings for the period had been distributed. The total net income allocated to each security is determined by adding both distributed and undistributed net income for the period.
- (iii) The net income allocated to each security is then divided by the weighted average number of outstanding shares for the period to determine the EPS for each security considered in the two-class method.

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

	Basic and Diluted EPS		Basic and Diluted EPS	
	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
	(in thousands)			
Net income	\$ 100,217	\$ 38,126	\$ 433,639	\$ 160,314
Less: net income attributable to non-controlling interests	23,289	10,960	81,271	28,824
Net income attributable to the Company	76,928	27,166	352,368	131,490
Less: Distributed and undistributed income attributable to participating securities	2,550	992	11,781	4,588
Distributed and undistributed income attributable to common shares	<u>\$ 74,378</u>	<u>\$ 26,174</u>	<u>\$ 340,587</u>	<u>\$ 126,902</u>

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended September 30,					
	2021			2022		
	Net Income Allocation	Shares ⁽¹⁾	Basic and Diluted EPS	Net Income Allocation	Shares ⁽¹⁾	Basic and Diluted EPS
	(in thousands, except for per share amounts)					
Common shares	\$ 74,378	130,594	\$ 0.57	\$ 26,174	122,193	\$ 0.21
Participating securities	2,550	4,477	\$ 0.57	992	4,631	\$ 0.21
Total Company	<u>\$ 76,928</u>			<u>\$ 27,166</u>		

	Nine Months Ended September 30,					
	2021			2022		
	Net Income Allocation	Shares ⁽¹⁾	Basic and Diluted EPS	Net Income Allocation	Shares ⁽¹⁾	Basic and Diluted EPS
	(in thousands, except for per share amounts)					
Common shares	\$ 340,587	130,441	\$ 2.61	\$ 126,902	125,341	\$ 1.01
Participating securities	11,781	4,512	\$ 2.61	4,588	4,532	\$ 1.01
Total Company	<u>\$ 352,368</u>			<u>\$ 131,490</u>		

(1) Represents the weighted average share count outstanding during the period.

14. Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to \$37.0 million for professional malpractice liability insurance and \$40.0 million for general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has designed a separate insurance program that responds to the risks of specific joint ventures. Most of the Company’s joint ventures are insured under a master program with an annual aggregate limit of up to \$80.0 million, subject to a sublimit aggregate ranging from \$23.0 million to \$33.0 million for most joint ventures. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company also maintains additional types of liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s professional and general liability insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Oklahoma City Subpoena. On August 24, 2020, the Company and Select Specialty Hospital – Oklahoma City, Inc. (“SSH–Oklahoma City”) received Civil Investigative Demands from the U.S. Attorney’s Office for the Western District of Oklahoma seeking responses to interrogatories and the production of various documents principally relating to the documentation, billing and reviews of medical services furnished to patients at SSH–Oklahoma City. The government’s investigation appears to be focused on respiratory therapy services and billings. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and is fully cooperating with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

Physical Therapy Billing. On October 7, 2021, the Company received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services, is investigating the Company in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, *et seq.* The letter specified that the investigation relates to the Company’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from the Company. In October and December 2021, the DOJ requested, and the Company furnished, records relating to six of the Company’s outpatient therapy clinics in Florida. In May and July 2022, the DOJ requested certain data relating to all of the Company’s outpatient therapy clinics nationwide, and sought information about the Company’s ability to produce additional data relating to the physical therapy services furnished by the Company and Concentra. The Company is fully cooperating with the DOJ on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

15. Subsequent Event

On November 2, 2022, the Company's board of directors declared a cash dividend of \$0.125 per share. The dividend will be payable on or about November 29, 2022, to stockholders of record as of the close of business on November 16, 2022.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words "may," "could," "would," "should," "believe," "expect," "anticipate," "plan," "target," "estimate," "project," "intend," and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, including the potential impact of the COVID-19 pandemic on those financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management's beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

- developments related to the COVID-19 pandemic including, but not limited to, the duration and severity of the pandemic, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;
- an inflationary environment could cause us to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;
- changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;
- the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;
- the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;
- a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
- acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;
- our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;
- private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
- the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;
- shortages in qualified nurses, therapists, physicians, or other licensed providers, or the inability to attract or retain healthcare professionals due to the heightened risk of infection related to the COVID-19 pandemic, could increase our operating costs significantly or limit our ability to staff our facilities;
- competition may limit our ability to grow and result in a decrease in our revenue and profitability;
- the loss of key members of our management team could significantly disrupt our operations;
- the effect of claims asserted against us could subject us to substantial uninsured liabilities;

- a security breach of our or our third-party vendors' information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
- other factors discussed from time to time in our filings with the SEC, including factors discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, and in our Quarterly Report on Form 10-Q for the three and six months ended June 30, 2022, as such risk factors may be updated from time to time in our periodic filings with the SEC.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

We began operations in 1997 and, based on number of facilities, are one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. As of September 30, 2022, we had operations in 46 states and the District of Columbia. We operated 105 critical illness recovery hospitals in 28 states, 31 rehabilitation hospitals in 12 states, and 1,933 outpatient rehabilitation clinics in 39 states and the District of Columbia. Concentra operated 519 occupational health centers in 41 states as of September 30, 2022. Concentra also provides contract services at employer worksites.

Our reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. We had revenue of \$4,752.1 million for the nine months ended September 30, 2022. Of this total, we earned approximately 35% of our revenue from our critical illness recovery hospital segment, approximately 14% from our rehabilitation hospital segment, approximately 18% from our outpatient rehabilitation segment, and approximately 28% from our Concentra segment. Our critical illness recovery hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs, and our rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to our critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Our Concentra segment consists of occupational health centers that provide workers' compensation injury care, physical therapy, and consumer health services as well as onsite clinics located at employer worksites that deliver occupational medicine services.

Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA, as defined below, is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our segments. Adjusted EBITDA is not a measure of financial performance under GAAP. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following table reconciles net income and income from operations to Adjusted EBITDA and should be referenced when we discuss Adjusted EBITDA:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
	(in thousands)			
Net income	\$ 100,217	\$ 38,126	\$ 433,639	\$ 160,314
Income tax expense	27,665	16,221	138,410	53,983
Interest expense	33,825	45,204	102,115	121,770
Interest income	—	—	(4,749)	—
Equity in earnings of unconsolidated subsidiaries	(11,452)	(8,084)	(33,180)	(19,648)
Income from operations	150,255	91,467	636,235	316,419
Stock compensation expense:				
Included in general and administrative	6,457	8,000	17,537	21,995
Included in cost of services	1,737	2,187	4,465	5,961
Depreciation and amortization	50,128	51,459	150,702	153,579
Adjusted EBITDA	\$ 208,577	\$ 153,113	\$ 808,939	\$ 497,954

Effects of the COVID-19 Pandemic on our Results of Operations

We have provided revenue and certain operating statistics below for each of our segments for the three and nine months ended September 30, 2022 and 2021, as well as the comparable pre-COVID-19 pandemic period in 2019. We believe this additional data provides insight into how each segment has performed in comparison to the year prior to the widespread emergence of COVID-19 in the United States. The effects of changes in the business environment following the COVID-19 pandemic, including the duration and extent of disruption on our operations, continues to create uncertainties about our future operating results and financial condition. Please refer to the risk factors in Item 1A and the section titled “*Effects of the COVID-19 Pandemic on our Results of Operations*” in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 for further discussion.

Critical Illness Recovery Hospital

	Revenue			Patient Days			Occupancy Rate			Number of Hospitals ⁽¹⁾		
	2019	2021	2022	2019	2021	2022	2019	2021	2022	2019	2021	2022
	(in thousands)											
Three Months Ended March 31	\$ 457,534	\$ 594,872	\$ 601,755	258,129	293,118	289,217	71 %	75 %	71 %	96	99	105
Three Months Ended June 30	461,143	544,059	545,908	262,860	272,981	273,133	69 %	69 %	67 %	99	99	105
Three Months Ended September 30	462,892	530,646	524,584	258,089	272,454	278,137	67 %	68 %	67 %	99	100	105
Nine Months Ended September 30	<u>\$ 1,381,569</u>	<u>\$ 1,669,577</u>	<u>\$ 1,672,247</u>	<u>779,078</u>	<u>838,553</u>	<u>840,487</u>	<u>69 %</u>	<u>70 %</u>	<u>68 %</u>	<u>99</u>	<u>100</u>	<u>105</u>

Rehabilitation Hospital

	Revenue			Patient Days			Occupancy Rate			Number of Hospitals ⁽¹⁾		
	2019	2021	2022	2019	2021	2022	2019	2021	2022	2019	2021	2022
	(in thousands)											
Three Months Ended March 31	\$ 154,558	\$ 207,804	\$ 220,634	82,816	102,439	103,802	76 %	84 %	84 %	18	20	20
Three Months Ended June 30	160,374	212,666	228,887	86,525	104,948	108,812	75 %	85 %	86 %	19	20	20
Three Months Ended September 30	173,369	212,434	229,387	89,454	102,953	109,076	75 %	82 %	85 %	19	20	20
Nine Months Ended September 30	<u>\$ 488,301</u>	<u>\$ 632,904</u>	<u>\$ 678,908</u>	<u>258,795</u>	<u>310,340</u>	<u>321,690</u>	<u>75 %</u>	<u>84 %</u>	<u>85 %</u>	<u>19</u>	<u>20</u>	<u>20</u>

Outpatient Rehabilitation

	Revenue			Visits			Working Days ⁽²⁾		
	2019	2021	2022	2019	2021	2022	2019	2021	2022
	(in thousands)								
Three Months Ended March 31	\$ 246,905	\$ 251,961	\$ 271,940	2,054,483	2,100,154	2,310,086	63	63	64
Three Months Ended June 30	261,891	280,409	287,258	2,203,505	2,404,861	2,450,912	64	64	64
Three Months Ended September 30	265,330	274,540	284,993	2,204,328	2,347,070	2,404,868	64	64	64
Nine Months Ended September 30	<u>\$ 774,126</u>	<u>\$ 806,910</u>	<u>\$ 844,191</u>	<u>6,462,316</u>	<u>6,852,085</u>	<u>7,165,866</u>	<u>191</u>	<u>191</u>	<u>192</u>

Concentra

	Revenue			Visits			Working Days ⁽²⁾		
	2019	2021	2022	2019	2021	2022	2019	2021	2022
	(in thousands)								
Three Months Ended March 31	\$ 396,321	\$ 422,840	\$ 423,423	2,911,607	2,795,574	3,116,898	63	63	64
Three Months Ended June 30	413,451	456,372	441,357	3,103,089	3,030,078	3,214,512	64	64	64
Three Months Ended September 30	421,900	442,190	444,576	3,150,903	3,223,631	3,273,031	64	64	64
Nine Months Ended September 30	<u>\$ 1,231,672</u>	<u>\$ 1,321,402</u>	<u>\$ 1,309,356</u>	<u>9,165,599</u>	<u>9,049,283</u>	<u>9,604,441</u>	<u>191</u>	<u>191</u>	<u>192</u>

-
- (1) Represents the number of hospitals included in our consolidated financial results at the end of each period presented and does not include the managed hospitals in which we have a minority ownership interest.
 - (2) Represents the number of days in which normal business operations were conducted during the periods presented.

Please refer to “*Summary Financial Results*” and “*Results of Operations*” for further discussion of our segment performance measures for the three and nine months ended September 30, 2021 and 2022. Please refer to “*Operating Statistics*” for further discussion regarding the uses and calculations of the metrics provided above, as well as the operating statistics data for each segment for the three and nine months ended September 30, 2021 and 2022.

Other Significant Events

Dividend Payments

On February 17, 2022, May 5, 2022, and August 2, 2022, our board of directors declared a cash dividend of \$0.125 per share. On March 16, 2022, June 1, 2022, and September 2, 2022, cash dividends totaling \$16.7 million, \$16.1 million, and \$15.9 million, respectively, were paid.

Summary Financial Results

Three Months Ended September 30, 2022

The following tables reconcile our segment performance measures to our consolidated operating results:

Three Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Revenue	\$ 524,584	\$ 229,387	\$ 284,993	\$ 444,576	\$ 84,254	\$ 1,567,794
Operating expenses	(513,691)	(179,856)	(259,278)	(355,086)	(125,397)	(1,433,308)
Depreciation and amortization	(16,055)	(6,994)	(8,157)	(17,781)	(2,472)	(51,459)
Other operating income	120	241	—	—	8,079	8,440
Income (loss) from operations	\$ (5,042)	\$ 42,778	\$ 17,558	\$ 71,709	\$ (35,536)	\$ 91,467
Depreciation and amortization	16,055	6,994	8,157	17,781	2,472	51,459
Stock compensation expense	—	—	—	535	9,652	10,187
Adjusted EBITDA	\$ 11,013	\$ 49,772	\$ 25,715	\$ 90,025	\$ (23,412)	\$ 153,113
Adjusted EBITDA margin	2.1 %	21.7 %	9.0 %	20.2 %	N/M	9.8 %

Three Months Ended September 30, 2021						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Revenue	\$ 530,646	\$ 212,434	\$ 274,540	\$ 442,190	\$ 74,411	\$ 1,534,221
Operating expenses	(473,401)	(168,358)	(235,778)	(344,529)	(113,501)	(1,335,567)
Depreciation and amortization	(12,972)	(6,869)	(7,319)	(20,419)	(2,549)	(50,128)
Other operating income	—	—	—	1,636	93	1,729
Income (loss) from operations	\$ 44,273	\$ 37,207	\$ 31,443	\$ 78,878	\$ (41,546)	\$ 150,255
Depreciation and amortization	12,972	6,869	7,319	20,419	2,549	50,128
Stock compensation expense	—	—	—	535	7,659	8,194
Adjusted EBITDA	\$ 57,245	\$ 44,076	\$ 38,762	\$ 99,832	\$ (31,338)	\$ 208,577
Adjusted EBITDA margin	10.8 %	20.7 %	14.1 %	22.6 %	N/M	13.6 %

Net income was \$38.1 million for the three months ended September 30, 2022, compared to \$100.2 million for the three months ended September 30, 2021.

The following table summarizes changes in segment performance measures for the three months ended September 30, 2022, compared to the three months ended September 30, 2021:

	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
Change in revenue	(1.1)%	8.0 %	3.8 %	0.5 %	13.2 %	2.2 %
Change in income from operations	(111.4)%	15.0 %	(44.2)%	(9.1)%	N/M	(39.1)%
Change in Adjusted EBITDA	(80.8)%	12.9 %	(33.7)%	(9.8)%	N/M	(26.6)%

N/M — Not meaningful.

Nine Months Ended September 30, 2022

The following tables reconcile our segment performance measures to our consolidated operating results:

Nine Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Revenue	\$ 1,672,247	\$ 678,908	\$ 844,191	\$ 1,309,356	\$ 247,380	\$ 4,752,082
Operating expenses	(1,605,368)	(537,153)	(758,279)	(1,038,842)	(366,007)	(4,305,649)
Depreciation and amortization	(45,276)	(20,971)	(24,316)	(55,323)	(7,693)	(153,579)
Other operating income (expense)	120	241	—	(19)	23,223	23,565
Income (loss) from operations	\$ 21,723	\$ 121,025	\$ 61,596	\$ 215,172	\$ (103,097)	\$ 316,419
Depreciation and amortization	45,276	20,971	24,316	55,323	7,693	153,579
Stock compensation expense	—	—	—	1,606	26,350	27,956
Adjusted EBITDA	\$ 66,999	\$ 141,996	\$ 85,912	\$ 272,101	\$ (69,054)	\$ 497,954
Adjusted EBITDA margin	4.0 %	20.9 %	10.2 %	20.8 %	N/M	10.5 %

Nine Months Ended September 30, 2021						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Revenue	\$ 1,669,577	\$ 632,904	\$ 806,910	\$ 1,321,402	\$ 213,911	\$ 4,644,704
Operating expenses	(1,444,043)	(487,526)	(696,186)	(1,038,053)	(325,796)	(3,991,604)
Depreciation and amortization	(38,958)	(20,868)	(21,855)	(61,547)	(7,474)	(150,702)
Other operating income	17,887	—	—	33,952	81,998	133,837
Income (loss) from operations	\$ 204,463	\$ 124,510	\$ 88,869	\$ 255,754	\$ (37,361)	\$ 636,235
Depreciation and amortization	38,958	20,868	21,855	61,547	7,474	150,702
Stock compensation expense	—	—	—	1,606	20,396	22,002
Adjusted EBITDA	\$ 243,421	\$ 145,378	\$ 110,724	\$ 318,907	\$ (9,491)	\$ 808,939
Adjusted EBITDA margin	14.6 %	23.0 %	13.7 %	24.1 %	N/M	17.4 %

Net income was \$160.3 million for the nine months ended September 30, 2022, compared to \$433.6 million for the nine months ended September 30, 2021.

The following table summarizes the changes in our segment performance measures for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021:

	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
Change in revenue	0.2 %	7.3 %	4.6 %	(0.9)%	15.6 %	2.3 %
Change in income from operations	(89.4)%	(2.8)%	(30.7)%	(15.9)%	N/M	(50.3)%
Change in Adjusted EBITDA	(72.5)%	(2.3)%	(22.4)%	(14.7)%	N/M	(38.4)%

N/M — Not meaningful.

Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 24, 2022, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report, or are likely to affect our financial performance and financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services (“HHS”) and CMS. Revenue generated directly from the Medicare program represented approximately 23% of our revenue for the nine months ended September 30, 2022, and for the year ended December 31, 2021.

Federal Health Care Program Changes in Response to the COVID-19 Pandemic

On January 31, 2020, HHS declared a public health emergency under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, in response to the COVID-19 outbreak in the United States. The HHS Secretary renewed the public health emergency determination for 90-day periods effective on April 26, 2020, July 25, 2020, October 23, 2020, January 21, 2021, April 21, 2021, July 20, 2021, October 18, 2021, January 16, 2022, April 16, 2022, July 15, 2022, and October 13, 2022. On March 13, 2020, President Trump declared a national emergency due to the COVID-19 pandemic and the HHS Secretary authorized the waiver or modification of certain requirements under Medicare, Medicaid, and the Children’s Health Insurance Program (“CHIP”) pursuant to section 1135 of the Social Security Act. Under this authority, CMS issued a number of blanket waivers that excuse health care providers or suppliers from specific program requirements. The following blanket waivers, while in effect, may impact our results of operations:

- i. Inpatient rehabilitation facilities (“IRFs”), IRF units, and hospitals and units applying to be classified as IRFs, can exclude patients admitted solely to respond to the emergency from the calculation of the “60 percent rule” thresholds to receive payment as an IRF.
- ii. Long-term care hospitals (“LTCHs”) are exempt from the greater-than-25-day average length of stay requirement for all cost reporting periods that include the COVID-19 public health emergency period. Hospitals seeking LTCH classification can exclude patient stays from the greater-than-25-day average length of stay requirement where the patient was admitted or discharged to meet the demands of the COVID-19 public health emergency.
- iii. Medicare expanded the types of health care professionals who can furnish telehealth services to include all those who are eligible to bill Medicare for their professional services. This allows health care professionals who were previously ineligible to furnish and bill for Medicare telehealth services, including physical therapists, occupational therapists, speech language pathologists, and others, to receive payment for Medicare telehealth services.
- iv. Medicare will not require out-of-state physician and non-physician practitioners to be licensed in the state where they are providing services when they are licensed in another state, subject to certain conditions and state or local licensure requirements.
- v. Many requirements under the hospital conditions of participation (“CoPs”) are waived during the emergency period to give hospitals more flexibility in treating COVID-19 patients.
- vi. Hospitals can operate temporary expansion locations without meeting the provider-based entity requirements or certain requirements in the physical environment CoP for hospitals during the emergency. This waiver also allows hospitals to change the status of their current provider-based department locations to meet patient needs as part of the state or local pandemic plan.
- vii. The HHS Secretary waived sanctions under the physician self-referral law (*i.e.*, Stark law) for certain types of remuneration and referral arrangements that are related to a COVID-19 purpose. The Office of the Inspector General (“OIG”) will also exercise enforcement discretion to not impose administrative sanctions under the federal anti-kickback statute for many payments covered by the Stark law waivers.

Pursuant to the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law 116-123, CMS has waived Medicare telehealth payment requirements during the emergency so that beneficiaries in all areas of the country (not just rural areas) can receive telehealth services, including in their homes, beginning on March 6, 2020. CMS issued additional waivers to permit more than 160 additional services to be furnished by telehealth, allow physicians to monitor patient services remotely, and fulfill face-to-face requirements in IRFs.

In addition to these agency actions, the CARES Act was enacted on March 27, 2020. It provides additional waivers, reimbursement, grants and other funds to assist health care providers during the COVID-19 public health emergency. Some of the CARES Act provisions that may impact our operations include:

- i. \$100 billion in appropriations for the Public Health and Social Services Emergency Fund to be used for preventing, preparing, and responding to COVID-19 and for reimbursing “eligible health care providers for health care related expenses or lost revenues that are attributable to coronavirus.” The Paycheck Protection Program and Health Care Enhancement Act, Public Law 116-139, added \$75 billion to this fund. The Consolidated Appropriations Act, 2021, added another \$3 billion to this fund. HHS began distributing these funds to providers in April 2020. HHS initially allocated funds for a general distribution to providers that received Medicare fee-for-service payments in 2019. Later general distributions required providers to submit an application to HHS. Other funding was allocated for targeted distributions for specific provider types. Recipients of payments must report data to HHS on the use of the funds via an online portal by specific deadlines established by HHS based on the date of the payment. Any funds that a provider does not apply towards expenses or lost revenue attributable to COVID-19 must be returned to HHS within 30 calendar days after the end of the applicable reporting period. All recipients of funds are subject to audit by HHS, the HHS OIG, or the Pandemic Response Accountability Committee. Audits may include examination of the accuracy of the data providers submitted to HHS in their applications for payments.
- ii. Expansion of the Accelerated and Advance Payment Program to advance three months of payments to Medicare providers. CMS has the ability to recoup the advanced payments through future Medicare claims. Section 2501 of the Continuing Appropriations Act, 2021 and Other Extensions Act, Public Law 116-159, modified the terms of repayment so that a provider can request no recoupment for one year after the advanced payment was issued, followed by a 25% offset the next 11 months, and a 50% offset the last 6 months. Any amounts that remain unpaid after 29 months will be subject to a 4% interest rate (instead of 10.25%). CMS began recouping advance payments on March 30, 2021, but the actual date for each provider is based on the first anniversary of when the provider received the first payment. CMS publishes repayment data every six months.
- iii. Temporary suspension of the 2% cut to Medicare payments due to sequestration so that, for the period of May 1, 2020, to December 31, 2020, the Medicare program would be exempt from any sequestration order. The Consolidated Appropriations Act, 2021, extended this temporary suspension of the 2% sequestration cut through March 31, 2021. The Medicare sequester relief bill, which became Public Law 117-7, extended the temporary suspension of the sequestration cut again, through December 31, 2021. To pay for the continued suspension of the sequestration cuts through December 31, 2021, Congress increased the sequestration cut that will apply in fiscal year 2030. The Protecting Medicare and American Farmers from Sequester Cuts Act, signed into law by President Biden on December 10, 2021, further extended the suspension of the sequestration cut through March 31, 2022, and reduces the sequestration cut to 1% from April 1, 2022, through June 30, 2022. The full 2% sequestration cut resumed on July 1, 2022. To pay for this relief, Congress increased the sequestration cut to Medicare payments to 2.25% for the first six months of fiscal year 2030 and to 3% for the final six months of fiscal year 2030. The same legislation defers an across-the-board 4% payment cut due to the American Rescue Plan from the FY 2022 Statutory Pay-As-You-Go (“PAYGO”) scorecard to the FY 2023 PAYGO scorecard.
- iv. Two waivers of Medicare statutory requirements regarding site neutral payment to LTCHs. The first waives the LTCH discharge payment percentage requirement (i.e., 50% rule) for the cost reporting period(s) that include the emergency period. The second waives application of the site neutral payment rate so that all LTCH cases admitted during the emergency period will be paid the LTCH-PPS standard federal rate.
- v. Waiver of the IRF 3-hour rule so that IRF services provided during the public health emergency period do not need to meet the coverage requirement that patients receive at least 3 hours of therapy a day or 15 hours of therapy per week.
- vi. Broader waiver authority for HHS under section 1135 of the Social Security Act to issue additional telehealth waivers.

Medicare Reimbursement of LTCH Services

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our critical illness recovery hospitals, which are certified by Medicare as LTCHs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our critical illness recovery hospitals are made in accordance with the long-term care hospital prospective payment system (“LTCH-PPS”).

Fiscal Year 2021. On September 18, 2020, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2021 (affecting discharges and cost reporting periods beginning on or after October 1, 2020, through September 30, 2021). Certain errors in the final rule were corrected in a document published December 7, 2020. The standard federal rate was set at \$43,755, an increase from the standard federal rate applicable during fiscal year 2020 of \$42,678. The update to the standard federal rate for fiscal year 2021 included a market basket increase of 2.3% with no productivity adjustment. The standard federal rate also included an area wage budget neutrality factor of 1.0016837. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at \$27,195, an increase from the fixed-loss amount in the 2020 fiscal year of \$26,778. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at \$29,064, an increase from the fixed-loss amount in the 2020 fiscal year of \$26,552.

Fiscal Year 2022. On August 13, 2021, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2022 (affecting discharges and cost reporting periods beginning on or after October 1, 2021, through September 30, 2022). The standard federal rate was set at \$44,714, an increase from the standard federal rate applicable during fiscal year 2021 of \$43,755. The update to the standard federal rate for fiscal year 2022 included a market basket increase of 2.6%, less a productivity adjustment of 0.7%. The standard federal rate also included an area wage budget neutrality factor of 1.002848. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at \$33,015, an increase from the fixed-loss amount in the 2021 fiscal year of \$27,195. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at \$30,988, an increase from the fixed-loss amount in the 2021 fiscal year of \$29,064.

Fiscal Year 2023. On August 10, 2022, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). The standard federal rate for fiscal year 2023 is \$46,433, an increase from the standard federal rate applicable during fiscal year 2022 of \$44,714. The update to the standard federal rate for fiscal year 2023 includes a market basket increase of 4.1%, less a productivity adjustment of 0.3%. The standard federal rate also includes an area wage budget neutrality factor of 1.0004304. As a result of the CARES Act, all LTCH cases are paid at the standard federal rate during the public health emergency. If the public health emergency ends during fiscal year 2023, then CMS will return to using the site-neutral payment rate for reimbursement of cases that do not meet the LTCH patient criteria. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS is \$38,518, an increase from the fixed-loss amount in the 2022 fiscal year of \$33,015. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is \$38,859, an increase from the fixed-loss amount in the 2022 fiscal year of \$30,988.

Medicare Reimbursement of IRF Services

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our rehabilitation hospitals, which are certified by Medicare as IRFs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our rehabilitation hospitals are made in accordance with the inpatient rehabilitation facility prospective payment system (“IRF-PPS”).

Fiscal Year 2021. On August 10, 2020, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2021 (affecting discharges and cost reporting periods beginning on or after October 1, 2020, through September 30, 2021). The standard payment conversion factor for discharges for fiscal year 2021 was set at \$16,856, an increase from the standard payment conversion factor applicable during fiscal year 2020 of \$16,489. The update to the standard payment conversion factor for fiscal year 2021 included a market basket increase of 2.4% with no productivity adjustment. CMS decreased the outlier threshold amount for fiscal year 2021 to \$7,906 from \$9,300 established in the final rule for fiscal year 2020.

Fiscal Year 2022. On August 4, 2021, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2022 (affecting discharges and cost reporting periods beginning on or after October 1, 2021, through September 30, 2022). The standard payment conversion factor for discharges for fiscal year 2022 was set at \$17,240, an increase from the standard payment conversion factor applicable during fiscal year 2021 of \$16,856. The update to the standard payment conversion factor for fiscal year 2022 included a market basket increase of 2.6%, less a productivity adjustment of 0.7%. CMS increased the outlier threshold amount for fiscal year 2022 to \$9,491 from \$7,906 established in the final rule for fiscal year 2021.

Fiscal Year 2023. On August 1, 2022, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). The standard payment conversion factor for discharges for fiscal year 2023 was set at \$17,878, an increase from the standard payment conversion factor applicable during fiscal year 2022 of \$17,240. The update to the standard payment conversion factor for fiscal year 2023 included a market basket increase of 4.2%, less a productivity adjustment of 0.3%. CMS increased the outlier threshold amount for fiscal year 2023 to \$12,526 from \$9,491 established in the final rule for fiscal year 2022.

Medicare Reimbursement of Outpatient Rehabilitation Clinic Services

Outpatient rehabilitation providers enroll in Medicare as a rehabilitation agency, a clinic, or a public health agency. The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. For services provided in 2017 through 2019, a 0.5% update was applied each year to the fee schedule payment rates, subject to an adjustment beginning in 2019 under the Merit-Based Incentive Payment System (“MIPS”). In 2019, CMS added physical and occupational therapists to the list of MIPS eligible clinicians. For these therapists in private practice, payments under the fee schedule are subject to adjustment in a later year based on their performance in MIPS according to established performance standards. Calendar year 2021 is the first year that payments were adjusted, based upon the therapist’s performance under MIPS in 2019. Providers in facility-based outpatient therapy settings are excluded from MIPS eligibility and therefore not subject to this payment adjustment. For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and the alternative payment models (“APMs”). In 2026 and subsequent years, eligible professionals participating in APMs who meet certain criteria would receive annual updates of 0.75%, while all other professionals would receive annual updates of 0.25%.

Each year from 2019 through 2024 eligible clinicians who receive a significant share of their revenues through an advanced APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and to promote the alignment of incentives across payors.

In the 2020 Medicare physician fee schedule final rule, CMS revised coding, documentation guidelines, and increased the valuation for evaluation and management (“E/M”) office visit codes, beginning in 2021. Because the Medicare physician fee schedule is budget-neutral, any revaluation of E/M services that will increase spending by more than \$20 million requires a budget neutrality adjustment. To increase values for the E/M codes while maintaining budget neutrality under the fee schedule, CMS cut the values of other codes to make up the difference, beginning in 2021.

In the 2021 Medicare physician fee schedule final rule, CMS increased the values for the E/M office visit codes and cuts to other specialty codes to maintain budget neutrality. As a result, therapy services provided in our outpatient rehabilitation clinics received an estimated 3.6% decrease in payment from Medicare in calendar year 2021. The Consolidated Appropriations Act, 2021, provided relief in the form of a one-time 3.75% increase in payments in calendar year 2021 for therapy services and other services paid under the physician fee schedule.

In the calendar year 2022 physician fee schedule final rule, CMS announced that Medicare payments for the therapy specialty are expected to decrease 1% in 2022. After CMS issued the final rule, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which provided in Section 3 a one-time 3% increase in payments in calendar year 2022 to offset most of the 3.75% cut to payments for therapy services and other services paid under the physician fee schedule. In the final rule, CMS also adopted its plan to transition the MIPS program to MIPS Value Pathways (“MVPs”). CMS will begin the transition to MVPs in 2023 with an initial set of MVPs in which reporting is voluntary. Beginning in 2026, multispecialty groups must form subgroups to report MVPs. CMS plans to develop more MVPs from 2024 to 2027 and is considering that MVP reporting would become mandatory in 2028. Each MVP would include population health claims-based measures and require clinicians to report on the Promoting Interoperability performance category measures. In addition, MVP participants would select certain quality measures and improvement activities and then report data for such measures and activities.

In the calendar year 2023 physician fee schedule proposed rule, CMS announced that it calculated the proposed payment rates for the physician fee schedule as if the 3% payment increase in calendar year 2022 from the Protecting Medicare and American Farmers from Sequester Cuts Act was never applied. The statute stated that the 3% payment increase for 2022 shall not be taken into account in determining the payment rates for subsequent years. As a result, physician fee schedule payments are expected to decrease in 2023, unless Congress provides additional funding for a payment increase as it has done the prior two years. CMS stated in the proposed rule that it expects that its proposed policies for 2023 would result in a 1% decrease in Medicare payments for the therapy specialty. The calendar year 2023 proposed rule also includes further development of MVPs. First, CMS proposed revisions to the first set of seven MVPs that it adopted in the calendar year 2022 final rule. CMS would remove certain improvement activities from these seven MVPs and add other quality measures that participants in these MVPs could choose to report data on. In addition, CMS proposed to add five new MVPs. If finalized, these new MVPs would be available for voluntary reporting for the calendar year 2023 performance period.

Modifiers to Identify Services of Physical Therapy Assistants or Occupational Therapy Assistants

In the Medicare physician fee schedule final rule for calendar year 2019, CMS established two new modifiers (CQ and CO) to identify services furnished in whole or in part by physical therapy assistants (“PTAs”) or occupational therapy assistants (“OTAs”). These modifiers were mandated by the Bipartisan Budget Act of 2018, which requires that claims for outpatient therapy services furnished in whole or part by therapy assistants on or after January 1, 2020, include the appropriate modifier. In the final 2020 Medicare physician fee schedule rule, CMS clarified that when the physical therapist is involved for the entire duration of the service and the PTA provides skilled therapy alongside the physical therapist, the CQ modifier is not required. Also, when the same service (code) is furnished separately by the physical therapist and PTA, CMS will apply the de minimis standard to each 15-minute unit of codes, not on the total physical therapist and PTA time of the service, allowing the separate reporting, on two different claim lines, of the number of units to which the new modifiers apply and the number of units to which the modifiers do not apply. In the calendar year 2022 physician fee schedule final rule, CMS implemented the final part of the requirements in the Bipartisan Budget Act of 2018 regarding PTA and OTA services. For dates of service on and after January 1, 2022, CMS pays for physical therapy and occupational therapy services provided by PTAs and OTAs at 85% of the otherwise applicable Part B payment amount. CMS modified the de minimis standard in the calendar year 2022 final rule to allow a timed service to be billed without the CQ or CO modifier when a PTA or OTA participates in providing care, but the physical therapist or occupational therapist meets the Medicare billing requirements without including the PTA’s or OTA’s minutes. This occurs when the physical therapist or occupational therapist provides more minutes than the 15-minute midpoint.

Operating Statistics

The following table sets forth operating statistics for each of our reportable segments for the periods presented. The operating statistics reflect data for the period of time we managed these operations. Our operating statistics include metrics we believe provide relevant insight about the number of facilities we operate, volume of services we provide to our patients, and average payment rates for services we provide. These metrics are utilized by management to monitor trends and performance in our businesses and therefore may be important to investors because management may assess our performance based in part on such metrics. Other healthcare providers may present similar statistics, and these statistics are susceptible to varying definitions. Our statistics as presented may not be comparable to other similarly titled statistics of other companies.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
Critical illness recovery hospital data:				
Number of consolidated hospitals—start of period ⁽¹⁾	99	105	99	104
Number of hospitals acquired	1	—	1	2
Number of hospital start-ups	—	—	—	1
Number of hospitals closed/sold	—	—	—	(2)
Number of consolidated hospitals—end of period ⁽¹⁾	100	105	100	105
Available licensed beds ⁽³⁾	4,369	4,509	4,369	4,509
Admissions ⁽³⁾⁽⁴⁾	9,250	9,056	28,135	27,319
Patient days ⁽³⁾⁽⁵⁾	272,454	278,137	838,553	840,487
Average length of stay (days) ⁽³⁾⁽⁶⁾	30	31	30	31
Revenue per patient day ⁽³⁾⁽⁷⁾	\$ 1,931	\$ 1,878	\$ 1,982	\$ 1,981
Occupancy rate ⁽³⁾⁽⁸⁾	68 %	67 %	70 %	68 %
Percent patient days—Medicare ⁽³⁾⁽⁹⁾	39 %	40 %	39 %	39 %
Rehabilitation hospital data:				
Number of consolidated hospitals—start of period ⁽¹⁾	20	20	19	20
Number of hospitals acquired	—	—	1	—
Number of hospital start-ups	—	—	—	—
Number of hospitals closed/sold	—	—	—	—
Number of consolidated hospitals—end of period ⁽¹⁾	20	20	20	20
Number of unconsolidated hospitals managed—end of period ⁽²⁾	10	11	10	11
Total number of hospitals (all)—end of period	30	31	30	31
Available licensed beds ⁽³⁾	1,361	1,391	1,361	1,391
Admissions ⁽³⁾⁽⁴⁾	7,243	7,517	21,734	22,149
Patient days ⁽³⁾⁽⁵⁾	102,953	109,076	310,340	321,690
Average length of stay (days) ⁽³⁾⁽⁶⁾	14	15	14	15
Revenue per patient day ⁽³⁾⁽⁷⁾	\$ 1,881	\$ 1,931	\$ 1,861	\$ 1,934
Occupancy rate ⁽³⁾⁽⁸⁾	82 %	85 %	84 %	85 %
Percent patient days—Medicare ⁽³⁾⁽⁹⁾	50 %	48 %	50 %	48 %
Outpatient rehabilitation data:				
Number of consolidated clinics—start of period	1,528	1,599	1,503	1,572
Number of clinics acquired	5	6	17	16
Number of clinic start-ups	15	9	37	34
Number of clinics closed/sold	(6)	(5)	(15)	(13)
Number of consolidated clinics—end of period	1,542	1,609	1,542	1,609
Number of unconsolidated clinics managed—end of period	308	324	308	324
Total number of clinics (all)—end of period	1,850	1,933	1,850	1,933
Number of visits ⁽³⁾⁽¹⁰⁾	2,347,070	2,404,868	6,852,085	7,165,866
Revenue per visit ⁽³⁾⁽¹¹⁾	\$ 102	\$ 103	\$ 103	\$ 103

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
Concentra data:				
Number of consolidated centers—start of period	518	518	517	518
Number of centers acquired	—	—	3	3
Number of center start-ups	2	1	2	1
Number of centers closed/sold	(1)	—	(3)	(3)
Number of consolidated centers—end of period	519	519	519	519
Number of onsite clinics operated—end of period	135	147	135	147
Number of visits ⁽³⁾⁽¹⁰⁾	3,223,631	3,273,031	9,049,283	9,604,441
Revenue per visit ⁽³⁾⁽¹¹⁾	\$ 124	\$ 128	\$ 125	\$ 127

- (1) Represents the number of hospitals included in our consolidated financial results at the end of each period presented.
- (2) Represents the number of hospitals which are managed by us at the end of each period presented. We have minority ownership interests in these businesses.
- (3) Data excludes locations managed by the Company. For purposes of our Concentra segment, onsite clinics are excluded.
- (4) Represents the number of patients admitted to our hospitals during the periods presented.
- (5) Each patient day represents one patient occupying one bed for one day during the periods presented.
- (6) Represents the average number of days in which patients were admitted to our hospitals. Average length of stay is calculated by dividing the number of patient days, as presented above, by the number of patients discharged from our hospitals during the periods presented.
- (7) Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.
- (8) Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.
- (9) Represents the portion of our patient days which are paid by Medicare. The Medicare patient day percentage is calculated by dividing the total number of patient days which are paid by Medicare by the total number of patient days, as presented above.
- (10) Represents the number of visits in which patients were treated at our outpatient rehabilitation clinics and Concentra centers during the periods presented.
- (11) Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for our Concentra segment, patient service revenue does not include onsite clinics.

Results of Operations

The following table outlines selected operating data as a percentage of revenue for the periods indicated:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2022	2021	2022
Revenue	100.0 %	100.0 %	100.0 %	100.0 %
Costs and expenses:				
Cost of services, exclusive of depreciation and amortization ⁽¹⁾	84.6	88.9	83.6	88.2
General and administrative	2.5	2.5	2.3	2.4
Depreciation and amortization	3.2	3.3	3.3	3.2
Total costs and expenses	90.3	94.7	89.2	93.8
Other operating income	0.1	0.5	2.9	0.5
Income from operations	9.8	5.8	13.7	6.7
Equity in earnings of unconsolidated subsidiaries	0.7	0.6	0.7	0.4
Interest income	—	—	0.1	—
Interest expense	(2.2)	(2.9)	(2.2)	(2.6)
Income before income taxes	8.3	3.5	12.3	4.5
Income tax expense	1.8	1.1	3.0	1.1
Net income	6.5	2.4	9.3	3.4
Net income attributable to non-controlling interests	1.5	0.7	1.7	0.6
Net income attributable to Select Medical Holdings Corporation	5.0 %	1.7 %	7.6 %	2.8 %

(1) Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense, and other operating costs.

The following table summarizes selected financial data by segment for the periods indicated:

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2022	% Change	2021	2022	% Change
(in thousands, except percentages)						
Revenue:						
Critical illness recovery hospital	\$ 530,646	\$ 524,584	(1.1)%	\$ 1,669,577	\$ 1,672,247	0.2 %
Rehabilitation hospital	212,434	229,387	8.0	632,904	678,908	7.3
Outpatient rehabilitation	274,540	284,993	3.8	806,910	844,191	4.6
Concentra	442,190	444,576	0.5	1,321,402	1,309,356	(0.9)
Other ⁽¹⁾	74,411	84,254	13.2	213,911	247,380	15.6
Total Company	<u>\$ 1,534,221</u>	<u>\$ 1,567,794</u>	<u>2.2 %</u>	<u>\$ 4,644,704</u>	<u>\$ 4,752,082</u>	<u>2.3 %</u>
Income (loss) from operations: ⁽²⁾						
Critical illness recovery hospital	\$ 44,273	\$ (5,042)	(111.4)%	\$ 204,463	\$ 21,723	(89.4)%
Rehabilitation hospital	37,207	42,778	15.0	124,510	121,025	(2.8)
Outpatient rehabilitation	31,443	17,558	(44.2)	88,869	61,596	(30.7)
Concentra	78,878	71,709	(9.1)	255,754	215,172	(15.9)
Other ⁽¹⁾	(41,546)	(35,536)	N/M	(37,361)	(103,097)	N/M
Total Company	<u>\$ 150,255</u>	<u>\$ 91,467</u>	<u>(39.1)%</u>	<u>\$ 636,235</u>	<u>\$ 316,419</u>	<u>(50.3)%</u>
Adjusted EBITDA: ⁽²⁾						
Critical illness recovery hospital	\$ 57,245	\$ 11,013	(80.8)%	\$ 243,421	\$ 66,999	(72.5)%
Rehabilitation hospital	44,076	49,772	12.9	145,378	141,996	(2.3)
Outpatient rehabilitation	38,762	25,715	(33.7)	110,724	85,912	(22.4)
Concentra	99,832	90,025	(9.8)	318,907	272,101	(14.7)
Other ⁽¹⁾	(31,338)	(23,412)	N/M	(9,491)	(69,054)	N/M
Total Company	<u>\$ 208,577</u>	<u>\$ 153,113</u>	<u>(26.6)%</u>	<u>\$ 808,939</u>	<u>\$ 497,954</u>	<u>(38.4)%</u>
Adjusted EBITDA margins: ⁽²⁾						
Critical illness recovery hospital	10.8 %	2.1 %		14.6 %	4.0 %	
Rehabilitation hospital	20.7	21.7		23.0	20.9	
Outpatient rehabilitation	14.1	9.0		13.7	10.2	
Concentra	22.6	20.2		24.1	20.8	
Other ⁽¹⁾	N/M	N/M		N/M	N/M	
Total Company	<u>13.6 %</u>	<u>9.8 %</u>		<u>17.4 %</u>	<u>10.5 %</u>	
Total assets:						
Critical illness recovery hospital	\$ 2,181,405	\$ 2,368,968		\$ 2,181,405	\$ 2,368,968	
Rehabilitation hospital	1,191,093	1,189,486		1,191,093	1,189,486	
Outpatient rehabilitation	1,339,452	1,377,010		1,339,452	1,377,010	
Concentra	2,609,361	2,309,392		2,609,361	2,309,392	
Other ⁽¹⁾	578,162	310,120		578,162	310,120	
Total Company	<u>\$ 7,899,473</u>	<u>\$ 7,554,976</u>		<u>\$ 7,899,473</u>	<u>\$ 7,554,976</u>	
Purchases of property and equipment:						
Critical illness recovery hospital	\$ 12,365	\$ 21,534		\$ 43,249	\$ 60,631	
Rehabilitation hospital	4,366	392		8,288	11,487	
Outpatient rehabilitation	9,481	10,098		24,264	28,826	
Concentra	11,353	9,074		31,624	28,030	
Other ⁽¹⁾	11,379	844		17,961	6,145	
Total Company	<u>\$ 48,944</u>	<u>\$ 41,942</u>		<u>\$ 125,386</u>	<u>\$ 135,119</u>	

(1) Other includes our corporate administration and shared services, as well as employee leasing services with our non-consolidating subsidiaries. Total assets include certain non-consolidating joint ventures and minority investments in other healthcare related businesses.

(2) During the three months ended September 30, 2022 and 2021, we recognized other operating income of \$8.4 million and \$1.7 million, respectively. During the nine months ended September 30, 2022 and 2021, we recognized other operating income of \$23.6 million and \$133.8 million, respectively. The impact of this income on the operating results of our segments is outlined within the tables presented under “*Summary Financial Results*” for the three and nine months ended September 30, 2022 and 2021.

N/M — Not meaningful.

Three Months Ended September 30, 2022, Compared to Three Months Ended September 30, 2021

In the following, we discuss our results of operations related to revenue, operating expenses, other operating income, Adjusted EBITDA, depreciation and amortization, income from operations, equity in earnings of unconsolidated subsidiaries, interest, income taxes, and net income attributable to non-controlling interests.

Please refer to “*Effects of the COVID-19 Pandemic on our Results of Operations*” above for further discussion.

Revenue

Our revenue increased 2.2% to \$1,567.8 million for the three months ended September 30, 2022, compared to \$1,534.2 million for the three months ended September 30, 2021.

Critical Illness Recovery Hospital Segment. Revenue was \$524.6 million for the three months ended September 30, 2022, compared to \$530.6 million for the three months ended September 30, 2021. The decline in revenue was caused by a decrease in our revenue per patient day, which was \$1,878 for the three months ended September 30, 2022, compared to \$1,931 for the three months ended September 30, 2021. The decline in revenue per patient day was due to a decline in patient acuity, as well as the reinstatement of the 2.0% cut to Medicare payments due to sequestration. Our patient days increased 2.1% to 278,137 days for the three months ended September 30, 2022, compared to 272,454 days for the three months ended September 30, 2021. We had 258,089 patient days during the three months ended September 30, 2019. Occupancy in our critical illness recovery hospitals was 67%, 68%, and 67% for the three months ended September 30, 2022, 2021, and 2019, respectively.

Rehabilitation Hospital Segment. Revenue increased 8.0% to \$229.4 million for the three months ended September 30, 2022, compared to \$212.4 million for the three months ended September 30, 2021. The increase in revenue was principally due to an increase in patient volume. Our patient days increased 5.9% to 109,076 days for the three months ended September 30, 2022, compared to 102,953 days for the three months ended September 30, 2021. Occupancy in our rehabilitation hospitals was 85%, 82%, and 75% for the three months ended September 30, 2022, 2021, and 2019, respectively. Revenue per patient day increased 2.7% to \$1,931 for the three months ended September 30, 2022, compared to \$1,881 for the three months ended September 30, 2021. We experienced an increase in our non-Medicare revenue per patient day during the three months ended September 30, 2022, compared to the three months ended September 30, 2021.

Outpatient Rehabilitation Segment. Revenue increased 3.8% to \$285.0 million for the three months ended September 30, 2022, compared to \$274.5 million for the three months ended September 30, 2021. The increase in revenue was primarily attributable to patient visits, which increased 2.5% to 2,404,868 visits for the three months ended September 30, 2022, compared to 2,347,070 visits for the three months ended September 30, 2021. The increase in visits resulted from the acquisition and development of clinics since September 30, 2021. Patient visits increased 9.1% for the three months ended September 30, 2022, as compared to the same period in September 30, 2019 (the comparable pre-COVID-19 pandemic period). Our revenue per visit was \$103 for the three months ended September 30, 2022, compared to \$102 for the three months ended September 30, 2021.

Concentra Segment. Revenue increased to \$444.6 million for the three months ended September 30, 2022, compared to \$442.2 million for the three months ended September 30, 2021. During the three months ended September 30, 2022, our revenue per visit increased to \$128, compared to \$124 for the three months ended September 30, 2021. We experienced a higher revenue per visit due to increases in the reimbursement rates payable pursuant to certain state fee schedules for workers’ compensation visits, as well as increases in our employer services rates. Our patient visits increased 1.5% to 3,273,031 visits for the three months ended September 30, 2022, compared to 3,223,631 visits for the three months ended September 30, 2021. Patient visits increased 3.9% for the three months ended September 30, 2022, as compared to the same period in September 30, 2019 (the comparable pre-COVID-19 pandemic period). Our revenue was adversely affected by the decline in revenue generated from COVID-19 screening and testing services. These services contributed \$2.5 million of revenue during the three months ended September 30, 2022, compared to \$20.6 million during the three months ended September 30, 2021.

Operating Expenses

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were \$1,433.3 million, or 91.4% of revenue, for the three months ended September 30, 2022, compared to \$1,335.6 million, or 87.1% of revenue, for the three months ended September 30, 2021. Our cost of services, a major component of which is labor expense, was \$1,393.8 million, or 88.9% of revenue, for the three months ended September 30, 2022, compared to \$1,297.7 million, or 84.6% of revenue, for the three months ended September 30, 2021. The increase in our operating expenses relative to our revenue was principally attributable to the incurrence of additional operating expenses within our critical illness recovery hospital and outpatient rehabilitation segments, as explained further within the “*Adjusted EBITDA*” discussion. General and administrative expenses were \$39.5 million, or 2.5% of revenue, for the three months ended September 30, 2022, compared to \$37.9 million, or 2.5% of revenue, for the three months ended September 30, 2021.

Other Operating Income

For the three months ended September 30, 2022, we had other operating income of \$8.4 million, compared to \$1.7 million for the three months ended September 30, 2021. The other operating income is primarily related to the recognition of payments received under the Provider Relief Fund for health care related expenses and lost revenues attributable to COVID-19.

For the three months ended September 30, 2022, other operating income of \$8.1 million, \$0.2 million, and \$0.1 million is included in the operating results of our other activities, rehabilitation hospital segment, and critical illness recovery hospital segment, respectively. For the three months ended September 30, 2021, other operating income of \$1.6 million and \$0.1 million is included within the operating results of our Concentra segment and other activities, respectively.

Adjusted EBITDA

Critical Illness Recovery Hospital Segment. Adjusted EBITDA was \$11.0 million for the three months ended September 30, 2022, compared to \$57.2 million for the three months ended September 30, 2021. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 2.1% for the three months ended September 30, 2022, compared to 10.8% for the three months ended September 30, 2021. The declines in Adjusted EBITDA and Adjusted EBITDA margin during the three months ended September 30, 2022, as compared to the three months ended September 30, 2021, were principally due to the incurrence of additional labor costs from our efforts to hire additional full-time nursing staff and improve retention among our employees, which led to increases in our sign-on and retention bonuses as well as education and orientation costs. We hired more full-time nursing staff in an effort to reduce our contract labor costs, which led to an increase in administrative nursing hours during the onboarding process. During the onboarding process, we continued to use contract labor to provide services to our patients. Our contracted registered nurses represented approximately 21.9% of our total registered nursing hours for the three months ended September 30, 2022, a decrease from approximately 29.6% during the three months ended September 30, 2021. The decline in our revenue per patient day for the three months ended September 30, 2022, as discussed above under “*Revenue*,” also contributed to the declines in Adjusted EBITDA and Adjusted EBITDA margin.

Rehabilitation Hospital Segment. Adjusted EBITDA increased 12.9% to \$49.8 million for the three months ended September 30, 2022, compared to \$44.1 million for the three months ended September 30, 2021. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 21.7% for the three months ended September 30, 2022, compared to 20.7% for the three months ended September 30, 2021. The increases in Adjusted EBITDA and Adjusted EBITDA margin were driven by increases in our revenue per patient day and patient volume, as described further above under “*Revenue*.”

Outpatient Rehabilitation Segment. Adjusted EBITDA was \$25.7 million for the three months ended September 30, 2022, compared to \$38.8 million for the three months ended September 30, 2021. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 9.0% for the three months ended September 30, 2022, compared to 14.1% for the three months ended September 30, 2021. Our Adjusted EBITDA and Adjusted EBITDA margin were affected by increases in both labor costs and other operating expenses for the three months ended September 30, 2022, as compared to the three months ended September 30, 2021.

Concentra Segment. Adjusted EBITDA was \$90.0 million for the three months ended September 30, 2022, compared to \$99.8 million for the three months ended September 30, 2021. Our Adjusted EBITDA margin for the Concentra segment was 20.2% for the three months ended September 30, 2022, compared to 22.6% for the three months ended September 30, 2021. The declines in Adjusted EBITDA and Adjusted EBITDA margin during the three months ended September 30, 2022, as compared to the three months ended September 30, 2021, were primarily caused by a decline in revenue generated from COVID-19 screening and testing services, as discussed above under “*Revenue*.” Our Concentra segment also recognized \$1.6 million of Provider Relief Funds during the three months ended September 30, 2021, as described further above under “*Other Operating Income*.”

Depreciation and Amortization

Depreciation and amortization expense was \$51.5 million for the three months ended September 30, 2022, compared to \$50.1 million for the three months ended September 30, 2021.

Income from Operations

For the three months ended September 30, 2022, we had income from operations of \$91.5 million, compared to \$150.3 million for the three months ended September 30, 2021. The increase in labor costs and other operating expenses experienced within our critical illness recovery hospital and outpatient rehabilitation segments were the primary cause of the decrease in income from operations, as discussed above under “*Adjusted EBITDA*.” Additionally, the decline in revenue per patient day for our critical illness recovery hospital segment, as discussed above under “*Revenue*,” contributed to this decline.

Equity in Earnings of Unconsolidated Subsidiaries

For the three months ended September 30, 2022, we had equity in earnings of unconsolidated subsidiaries of \$8.1 million, compared to \$11.5 million for the three months ended September 30, 2021. The earnings of the rehabilitation businesses in which we are a minority owner declined during the three months ended September 30, 2022.

Interest

Our term loan is subject to an interest rate cap, which limits the 1-month LIBOR rate to 1.0% on \$2.0 billion of principal outstanding under the term loan. The 1-month LIBOR rate was 3.14% at September 30, 2022, compared to 0.08% at September 30, 2021. Accordingly, the interest rate cap mitigated our exposure to increases in 1-month LIBOR in excess of 1.0% during the three months ended September 30, 2022. Interest expense was \$45.2 million for the three months ended September 30, 2022, compared to \$33.8 million for the three months ended September 30, 2021. The increase in interest expense was caused by the borrowings we made under our revolving facility during the three months ended September 30, 2022, as well as an increase in the 1-month LIBOR rate, as described further above.

Income Taxes

We recorded income tax expense of \$16.2 million for the three months ended September 30, 2022, which represented an effective tax rate of 29.8%. We recorded income tax expense of \$27.7 million for the three months ended September 30, 2021, which represented an effective tax rate of 21.6%. For the three months ended September 30, 2022, the higher effective tax rate resulted primarily from the effect of a change in Pennsylvania’s corporate income tax rate on our net deferred tax asset. This legislation was enacted during the three months ended September 30, 2022.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was \$11.0 million for the three months ended September 30, 2022, compared to \$23.3 million for the three months ended September 30, 2021. The reduction in net income attributable to non-controlling interests was principally due to a change in our ownership interest of Concentra Group Holdings Parent. Since September 30, 2021, we have acquired substantially all of the outstanding membership interests of Concentra Group Holdings Parent.

Nine Months Ended September 30, 2022, Compared to Nine Months Ended September 30, 2021

In the following, we discuss our results of operations related to revenue, operating expenses, other operating income, Adjusted EBITDA, depreciation and amortization, income from operations, equity in earnings of unconsolidated subsidiaries, interest, income taxes, and net income attributable to non-controlling interests.

Please refer to “*Effects of the COVID-19 Pandemic on our Results of Operations*” above for further discussion.

Revenue

Our revenue increased 2.3% to \$4,752.1 million for the nine months ended September 30, 2022, compared to \$4,644.7 million for the nine months ended September 30, 2021.

Critical Illness Recovery Hospital Segment. Revenue increased to \$1,672.2 million for the nine months ended September 30, 2022, compared to \$1,669.6 million for the nine months ended September 30, 2021. Our patient days increased to 840,487 for the nine months ended September 30, 2022, compared to 838,553 days for the nine months ended September 30, 2021. Occupancy in our critical illness recovery hospitals was 68%, 70%, and 69% for the nine months ended September 30, 2022, 2021, and 2019, respectively. Revenue per patient day was \$1,981 for the nine months ended September 30, 2022, compared to \$1,982 for the nine months ended September 30, 2021. Our Medicare revenue per patient day decreased during the nine months ended September 30, 2022, due to a decline in patient acuity, as well as the reinstatement of the 2.0% cut to Medicare payments due to sequestration.

Rehabilitation Hospital Segment. Revenue increased 7.3% to \$678.9 million for the nine months ended September 30, 2022, compared to \$632.9 million for the nine months ended September 30, 2021. The increase in revenue was principally due to an increase in revenue per patient day. Our revenue per patient day increased 3.9% to \$1,934 for the nine months ended September 30, 2022, compared to \$1,861 for the nine months ended September 30, 2021. We experienced increases in both our Medicare and non-Medicare revenue per patient day during the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. Our patient days increased 3.7% to 321,690 days for the nine months ended September 30, 2022, compared to 310,340 days for the nine months ended September 30, 2021. Occupancy in our rehabilitation hospitals was 85%, 84%, and 75% for the nine months ended September 30, 2022, 2021, and 2019, respectively.

Outpatient Rehabilitation Segment. Revenue increased 4.6% to \$844.2 million for the nine months ended September 30, 2022, compared to \$806.9 million for the nine months ended September 30, 2021. The increase in revenue was primarily attributable to patient visits, which increased 4.6% to 7,165,866 visits for the nine months ended September 30, 2022, compared to 6,852,085 visits for the nine months ended September 30, 2021. The increase in visits resulted from the acquisition and development of clinics since September 30, 2021, as well as improvement in volume in our clinics which operated during both the nine months ended September 30, 2022 and 2021. Patient visits increased 10.9% for the nine months ended September 30, 2022, as compared to the same period in September 30, 2019 (the comparable pre-COVID-19 pandemic period). Our revenue per visit was \$103 for both the nine months ended September 30, 2022 and 2021.

Concentra Segment. Revenue was \$1,309.4 million for the nine months ended September 30, 2022, compared to \$1,321.4 million for the nine months ended September 30, 2021. The decrease is attributable to a decline in revenue generated from COVID-19 screening and testing services. These services contributed \$19.3 million of revenue during the nine months ended September 30, 2022, compared to \$127.2 million during the nine months ended September 30, 2021. The decline in revenue was partially offset by increases in both revenue per visit and patient visits. Our revenue per visit increased to \$127 for the nine months ended September 30, 2022, compared to \$125 for the nine months ended September 30, 2021. We experienced a higher revenue per visit due to increases in the reimbursement rates payable pursuant to certain state fee schedules for workers’ compensation visits, as well as increases in our employer services rates. Our patient visits increased 6.1% to 9,604,441 for the nine months ended September 30, 2022, compared to 9,049,283 visits for the nine months ended September 30, 2021. Patient visits increased 4.8% for the nine months ended September 30, 2022, as compared to the same period in September 30, 2019 (the comparable pre-COVID-19 pandemic period).

Operating Expenses

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were \$4,305.6 million, or 90.6% of revenue, for the nine months ended September 30, 2022, compared to \$3,991.6 million, or 85.9% of revenue, for the nine months ended September 30, 2021. Our cost of services, a major component of which is labor expense, was \$4,191.4 million, or 88.2% of revenue, for the nine months ended September 30, 2022, compared to \$3,882.6 million, or 83.6% of revenue, for the nine months ended September 30, 2021. The increase in our operating expenses relative to our revenue was principally attributable to the incurrence of additional operating expenses within our critical illness recovery hospital, rehabilitation hospitals, and outpatient rehabilitation segments, as explained further within the “*Adjusted EBITDA*” discussion. General and administrative expenses were \$114.3 million, or 2.4% of revenue, for the nine months ended September 30, 2022, compared to \$109.0 million, or 2.3% of revenue, for the nine months ended September 30, 2021.

Other Operating Income

For the nine months ended September 30, 2022, we had other operating income of \$23.6 million, compared to \$133.8 million for the nine months ended September 30, 2021. The other operating income recognized is primarily related to the recognition of payments received under the Provider Relief Fund for health care related expenses and lost revenues attributable to COVID-19. Additionally, during the nine months ended September 30, 2021, our critical illness recovery hospital segment recognized \$17.9 million of other operating income related to the outcome of litigation with CMS.

For the nine months ended September 30, 2022, other operating income of \$23.2 million, \$0.2 million, and \$0.1 million is included in the operating results of our other activities, rehabilitation hospital segment, and critical illness recovery hospital segment, respectively. For the nine months ended September 30, 2021, other operating income of \$82.0 million, \$34.0 million, and \$17.9 million is included in the operating results of our other activities, Concentra segment, and critical illness recovery hospital segment, respectively.

Adjusted EBITDA

Critical Illness Recovery Hospital Segment. Adjusted EBITDA was \$67.0 million for the nine months ended September 30, 2022, compared to \$243.4 million for the nine months ended September 30, 2021. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 4.0% for the nine months ended September 30, 2022, compared to 14.6% for the nine months ended September 30, 2021. The declines in Adjusted EBITDA and Adjusted EBITDA margin during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021, were principally due to the incurrence of additional labor costs from our efforts to hire additional full-time nursing staff and improve retention among our employees which led to increases in our sign-on and retention bonuses as well as education and orientation costs. We hired more full-time nursing staff in an effort to reduce our contract labor costs, which led to an increase in administrative nursing hours during the onboarding process. The increased contract labor costs are due to both increased rates and higher utilization. Our contract labor costs for registered nurses were approximately 8.3% higher during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021. For the nine months ended September 30, 2022, our contracted registered nurses represented approximately 30.9% of our total registered nursing hours, compared to approximately 30.0% for the nine months ended September 30, 2021. Contract registered nursing hours as a percentage of our total registered nursing hours were 21.9%, 32.9%, 37.5%, and 37.5% for the three months ended September 30, 2022, June 30, 2022, March 31, 2022, and December 31, 2021, respectively. Our critical illness recovery hospitals segment also recognized \$17.9 million of other operating income related to the outcome of litigation with CMS during the nine months ended September 30, 2021.

Rehabilitation Hospital Segment. Adjusted EBITDA was \$142.0 million for the nine months ended September 30, 2022, compared to \$145.4 million for the nine months ended September 30, 2021. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 20.9% for the nine months ended September 30, 2022, compared to 23.0% for the nine months ended September 30, 2021. The declines in Adjusted EBITDA and Adjusted EBITDA margin during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021, were primarily attributable to the incurrence of additional labor costs. Constrained staffing due to a shortage of healthcare workers has led to increases in incentive and retention pay for our employees and greater dependence on higher-cost contract clinical workers. The demand for healthcare professionals has caused the cost of contract clinical labor to rise significantly during the nine months ended September 30, 2022.

Outpatient Rehabilitation Segment. Adjusted EBITDA was \$85.9 million for the nine months ended September 30, 2022, compared to \$110.7 million for the nine months ended September 30, 2021. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 10.2% for the nine months ended September 30, 2022, compared to 13.7% for the nine months ended September 30, 2021. Our Adjusted EBITDA and Adjusted EBITDA margin were affected by increases in both labor costs and other operating expenses for the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021.

Concentra Segment. Adjusted EBITDA was \$272.1 million for the nine months ended September 30, 2022, compared to \$318.9 million for the nine months ended September 30, 2021. Our Adjusted EBITDA margin for the Concentra segment was 20.8% for the nine months ended September 30, 2022, compared to 24.1% for the nine months ended September 30, 2021. The declines in Adjusted EBITDA and Adjusted EBITDA margin during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021, were primarily caused by a decline in revenue generated from COVID-19 screening and testing services, as discussed above under “*Revenue.*” Our Concentra segment also recognized \$34.0 million of Provider Relief Funds during the nine months ended September 30, 2021, as described further above under “*Other Operating Income.*”

Depreciation and Amortization

Depreciation and amortization expense was \$153.6 million for the nine months ended September 30, 2022, compared to \$150.7 million for the nine months ended September 30, 2021.

Income from Operations

For the nine months ended September 30, 2022, we had income from operations of \$316.4 million, compared to \$636.2 million for the nine months ended September 30, 2021. The increase in labor costs and other operating expenses experienced within our critical illness recovery hospital, rehabilitation hospital, and outpatient rehabilitation segments were the primary cause of the decrease in income from operations, as discussed above under “*Adjusted EBITDA.*” Additionally, we recognized other operating income of \$23.6 million during the nine months ended September 30, 2022, compared to \$133.8 million during the nine months ended September 30, 2021, as described further under “*Other Operating Income.*”

Equity in Earnings of Unconsolidated Subsidiaries

For the nine months ended September 30, 2022, we had equity in earnings of unconsolidated subsidiaries of \$19.6 million, compared to \$33.2 million for the nine months ended September 30, 2021. The earnings of the rehabilitation businesses in which we are a minority owner declined during the nine months ended September 30, 2022.

Interest

Our term loan is subject to an interest rate cap, which limits the 1-month LIBOR rate to 1.0% on \$2.0 billion of principal outstanding under the term loan. The 1-month LIBOR rate was 3.14% at September 30, 2022, compared to 0.08% at September 30, 2021. Accordingly, the interest rate cap mitigated our exposure to increases in 1-month LIBOR in excess of 1.0% during the nine months ended September 30, 2022. Interest expense was \$121.8 million for the nine months ended September 30, 2022, compared to \$102.1 million for the nine months ended September 30, 2021. The increase in interest expense was caused by the borrowings we made under our revolving facility during the nine months ended September 30, 2022, as well as an increase in the 1-month LIBOR rate, as described further above.

For the nine months ended September 30, 2021, we recognized interest income of \$4.7 million. The interest income was related to the outcome of litigation with CMS.

Income Taxes

We recorded income tax expense of \$54.0 million for the nine months ended September 30, 2022, which represented an effective tax rate of 25.2%. We recorded income tax expense of \$138.4 million for the nine months ended September 30, 2021, which represented an effective tax rate of 24.2%. For the nine months ended September 30, 2022, the higher effective tax rate resulted primarily from the effect of a change in Pennsylvania’s corporate income tax rate on our net deferred tax asset and a greater effect of nondeductible expenses on our income before income taxes.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was \$28.8 million for the nine months ended September 30, 2022, compared to \$81.3 million for the nine months ended September 30, 2021. The reduction in net income attributable to non-controlling interests was principally due to a change in our ownership interest of Concentra Group Holdings Parent. Since September 30, 2021, we have acquired substantially all of the outstanding membership interests of Concentra Group Holdings Parent. The reduction in net income attributable to non-controlling interests was also due to a decline in the net income of our less than wholly owned subsidiaries. Many of these subsidiaries were impacted by increases in labor costs during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021.

Liquidity and Capital Resources

Cash Flows for the Nine Months Ended September 30, 2022 and Nine Months Ended September 30, 2021

In the following, we discuss cash flows from operating activities, investing activities, and financing activities.

	Nine Months Ended September 30,	
	2021	2022
	(in thousands)	
Cash flows provided by operating activities	\$ 461,980	\$ 272,281
Cash flows used in investing activities	(157,326)	(169,105)
Cash flows used in financing activities	(133,732)	(69,263)
Net increase in cash and cash equivalents	170,922	33,913
Cash and cash equivalents at beginning of period	577,061	74,310
Cash and cash equivalents at end of period	\$ 747,983	\$ 108,223

Operating activities provided \$272.3 million of cash flows for the nine months ended September 30, 2022, compared to \$462.0 million of cash flows for the nine months ended September 30, 2021. The decrease in cash flows from operating activities was primarily due to a reduction in our operating income.

Our days sales outstanding was 53 days at September 30, 2022, compared to 52 days at December 31, 2021. Our days sales outstanding was 54 days at September 30, 2021, compared to 56 days at December 31, 2020. Our days sales outstanding will fluctuate based upon variability in our collection cycles and patient volumes.

Investing activities used \$169.1 million of cash flows for the nine months ended September 30, 2022. The principal uses of cash were \$135.1 million for purchases of property and equipment and \$39.4 million for investments in and acquisitions of businesses. The cash outflows were offset in part by proceeds received from the sale of assets of \$5.4 million. Investing activities used \$157.3 million of cash flows for the nine months ended September 30, 2021. The principal uses of cash were \$125.4 million for purchases of property and equipment and \$43.2 million for investments in and acquisitions of businesses. The cash outflows were offset in part by proceeds received from the sale of assets of \$11.3 million.

Financing activities used \$69.3 million of cash flows for the nine months ended September 30, 2022. The principal uses of cash were \$193.6 million for repurchases of common stock, \$48.7 million of dividend payments to common stockholders, and \$40.7 million for distributions to and purchases of non-controlling interests. The cash outflows were offset in part by net borrowings under our revolving facility of \$220.0 million. Financing activities used \$133.7 million of cash flows for the nine months ended September 30, 2021. The principal uses of cash were \$66.1 million for repurchases of common stock, \$50.4 million for distributions to and purchases of non-controlling interests and \$33.8 million of dividend payments to common stockholders.

Capital Resources

Working capital. We had net working capital of \$20.5 million at September 30, 2022, compared to a net working capital deficit of \$133.6 million at December 31, 2021. The reduction of the working capital deficit was primarily due to an increase in our cash and cash equivalents and a reduction in our liability related to the payments we received under the Accelerated and Advance Payment Program.

Credit facilities. At September 30, 2022, Select had outstanding borrowings under its credit facilities consisting of a \$2,103.4 million term loan (excluding unamortized original issue discounts and debt issuance costs of \$10.2 million) and borrowings of \$380.0 million under its revolving facility. At September 30, 2022, Select had \$213.5 million of availability under its revolving facility after giving effect to \$56.5 million of outstanding letters of credit.

Stock Repurchase Program. Holdings' board of directors has authorized a common stock repurchase program to repurchase up to \$1.0 billion worth of shares of its common stock. The common stock repurchase program will remain in effect until December 31, 2023, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings funds this program with cash on hand and borrowings under its revolving facility. During the nine months ended September 30, 2022, Holdings repurchased 7,883,195 shares at a cost of approximately \$185.1 million, or \$23.48 per share, which includes transaction costs. Since the inception of the program through September 30, 2022, Holdings has repurchased 48,234,823 shares at a cost of approximately \$600.3 million, or \$12.45 per share, which includes transaction costs.

Use of Capital Resources. We may from time to time pursue opportunities to develop new joint venture relationships with large, regional health systems and other healthcare providers. We also intend to open new outpatient rehabilitation clinics and occupational health centers in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow through opportunistic acquisitions.

Liquidity

The duration and extent of the impact from the COVID-19 pandemic on our operations and liquidity depends on future developments that cannot be accurately predicted at this time; however, we believe our internally generated cash flows and borrowing capacity under our revolving facility will allow us to finance our operations in both the short and long term. As of September 30, 2022, we had cash and cash equivalents of \$108.2 million and \$213.5 million of availability under the revolving facility after giving effect to \$380.0 million of outstanding borrowings and \$56.5 million of letters of credit.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Dividend

On November 2, 2022, our board of directors declared a cash dividend of \$0.125 per share. The dividend will be payable on or about November 29, 2022 to stockholders of record as of the close of business on November 16, 2022.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of our board of directors after taking into account various factors, including, but not limited to, our financial condition, operating results, available cash and current and anticipated cash needs, the terms of our indebtedness, and other factors our board of directors may deem to be relevant.

Effects of Inflation

The healthcare industry is labor intensive and our largest expenses are labor related costs. Wage and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. We have recently experienced higher labor costs related to the current inflationary environment and competitive labor market. In addition, suppliers have passed along rising costs to us in the form of higher prices. We cannot predict our ability to pass along cost increases to our customers.

Recent Accounting Pronouncements

There were no new accounting standards issued between December 31, 2021, and September 30, 2022, which will have a material effect on the financial statements upon adoption.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under our credit facilities, which generally bear interest rates that are indexed against LIBOR.

At September 30, 2022, Select had outstanding borrowings under its credit facilities consisting of a \$2,103.4 million term loan (excluding unamortized original issue discounts and debt issuance costs of \$10.2 million) and \$380.0 million of borrowings under its revolving facility.

In order to mitigate our exposure to rising interest rates, we entered into an interest rate cap transaction to limit our 1-month LIBOR rate to 1.0% on \$2.0 billion of principal outstanding under our term loan. The agreement applies to interest payments through September 30, 2024. As of September 30, 2022, the 1-month LIBOR rate was 3.14%. As of September 30, 2022, \$103.4 million of our term loan borrowings are subject to variable interest rates.

As of September 30, 2022, each 0.25% increase in market interest rates will impact the interest expense on our variable rate debt by \$1.2 million.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, as of September 30, 2022, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the third quarter ended September 30, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to the “*Litigation*” section contained within Note 14 – Commitments and Contingencies of the notes to our condensed consolidated financial statements included herein.

ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the three and six months ended June 30, 2022.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

Holdings’ board of directors authorized a common stock repurchase program to repurchase up to \$1.0 billion worth of shares of its common stock. The program will remain in effect until December 31, 2023, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate.

The following table provides information regarding repurchases of our common stock during the three months ended September 30, 2022.

	Total Number of Shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
July 1 - July 31, 2022 ⁽¹⁾	569,272	\$ 26.33	315,762	\$ 399,677,961
August 1 - August 31, 2022	—	—	—	399,677,961
September 1 - September 30, 2022	—	—	—	399,677,961
Total	569,272	\$ 26.33	315,762	\$ 399,677,961

(1) Includes share repurchases under our common stock repurchase program and common stock surrendered to us to satisfy tax withholding obligations associated with the vesting of restricted shares issued to employees, pursuant to the provisions of our equity incentive plans.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Number	Description
31.1	<u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2	<u>Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1	<u>Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL HOLDINGS CORPORATION

By: /s/ Martin F. Jackson

Martin F. Jackson

Executive Vice President and Chief Financial Officer

(Duly Authorized Officer)

By: /s/ Scott A. Romberger

Scott A. Romberger

Senior Vice President, Chief Accounting Officer

(Principal Accounting Officer)

Dated: November 3, 2022